



OPEN ACCESS

# Comparison of cooled versus conventional radiofrequency treatment of the genicular nerves for chronic knee pain: a multicenter non-inferiority randomized pilot trial (COCOGEN trial)

Thibaut Vanneste <sup>1,2</sup> Amy Belba <sup>1,3</sup> Jan Willem Kallewaard,<sup>4</sup> Sander M J van Kuijk,<sup>5</sup> Marloes Gelissen,<sup>2</sup> Peter Emans,<sup>6</sup> Johan Bellemans,<sup>3,7,8</sup> Kristof Smeets,<sup>9</sup> Chris Terwiel,<sup>4</sup> Koen Van Boxem,<sup>1,2</sup> Micha Sommer,<sup>2</sup> Jan Van Zundert <sup>1,2</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rapm-2022-104054>).

For numbered affiliations see end of article.

## Correspondence to

Dr Thibaut Vanneste, Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Multidisciplinary Pain Center, Ziekenhuis Oost-Limburg, Genk 3600, Belgium; [Thibaut.Vanneste@zol.be](mailto:Thibaut.Vanneste@zol.be)

Received 14 September 2022  
Accepted 2 January 2023

## ABSTRACT

**Background** Radiofrequency (RF) treatment of the genicular nerves has the potential to reduce chronic knee pain due to osteoarthritis or persistent postsurgical pain, however, a direct comparison between the two main modalities used, conventional and cooled, is lacking.

**Methods** This double blind, non-inferiority, pilot, randomized controlled trial compared the effects of cooled and conventional RF in chronic knee pain patients suffering from osteoarthritis or persistent postsurgical pain after total knee arthroplasty. Patients were randomized following a 1:1 rate. The primary outcome was the proportion of patients with  $\geq 50\%$  pain reduction at 3 months postintervention. Other outcomes were knee pain, functionality, quality of life, emotional health, and adverse events up to 6 months postintervention. Conventional RF treatment was tested for non-inferiority to cooled in reducing knee pain at 3 months follow-up.

**Results** Forty-nine of 70 patients were included, of which 47 completed a 3-month follow-up. The primary outcome was achieved in 4 of 23 patients treated with conventional RF (17%) vs in 8 of 24 with cooled (33%) ( $p=0,21$ ). Results from the non-inferiority comparison were inconclusive in relation to the non-inferiority margin. There was no statistically significant difference between secondary outcomes. There were no serious adverse events.

**Conclusions** Both conventional and cooled RF treatment reduced pain in the osteoarthritis and persistent postsurgical pain population. This pilot study did not demonstrate statistically significant differences in the proportion of patients experiencing  $\geq 50\%$  pain reduction between techniques. The non-inferiority analysis was inconclusive. These results warrant further research.

**Trial registration number** NCT03865849.

## INTRODUCTION

Chronic knee pain is most often caused by osteoarthritis (OA) of the knee, a degenerative process that affects joint cartilage and the subchondral bone.<sup>1</sup> OA causes pain, stiffness and loss of function leading to psychological and sleeping disorders, and a diminished quality of life. Worldwide,

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Conventional and cooled radiofrequency of the genicular nerves are safe procedures that reduce therapy resistant chronic knee pain due to osteoarthritis and persistent postsurgical pain.

## WHAT THIS STUDY ADDS

⇒ This pilot randomized controlled trial comparing cooled and conventional radiofrequency modalities suggests that pain reduction is higher in the cooled radiofrequency group, however, the analysis is inconclusive due to the small number of patients included.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Cooled radiofrequency of the genicular nerves might lead to better symptom reduction in chronic knee pain patients compared with conventional radiofrequency. However, the results in this study were not statistical significant, therefore, a large, powered randomized controlled trial is necessary to prove statistical significance.

the prevalence of knee OA is increasing reflecting the aging population and the increasing prevalence of obesity, a well-known risk factor.<sup>2</sup> Non-surgical treatment options, including pharmacological therapy, physiotherapy and lifestyle changes, are often insufficient and frequently associated with side effects. Consequently, many OA patients undergo a total knee arthroplasty (TKA).<sup>3</sup>

Unfortunately, a TKA is not a guarantee of success, given that the incidence of persistent postsurgical pain (PPSP) and functional limitation after TKA is as high as 53%.<sup>4</sup> Patients suffering from OA that have exhausted conservative treatments and are not surgical candidates (eg, due to comorbidities or very young age) and PPSP patients only have few therapeutical options.<sup>5</sup> Radiofrequency (RF) treatment of the genicular nerves might be a viable treatment option.



© American Society of Regional Anesthesia & Pain Medicine 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

**To cite:** Vanneste T, Belba A, Kallewaard JW, et al. *Reg Anesth Pain Med* Epub ahead of print: [please include Day Month Year]. doi:10.1136/rapm-2022-104054

RF treatment of the genicular nerves is a minimally invasive treatment that reduces pain by interrupting the conduction of nociceptive stimuli through the application of a radiofrequency current adjacent to the responsible nerves. Recent systematic reviews indicate that RF is a safe and effective treatment in patients with OA of the knee, and to a lesser extent, in PPSP patients after TKA.<sup>6–8</sup> Two RF modalities, conventional and cooled RF, are commonly used to target the superomedial, the superolateral and the inferomedial genicular nerve. Prior studies suggest a higher success rate and a longer effect of cooled compared with conventional RF due to an increased lesion size, however, until present, no direct comparative studies have been performed in a randomised controlled trial (RCT).<sup>6,9</sup> This knowledge gap warrants further comparative studies. This is the first prospective study to directly compare the effectiveness of conventional and cooled RF in patients with chronic knee pain due to OA or PPSP after TKA. The primary goal was to provide an estimate of clinical treatment effects (pain, physical functioning, mental health, medication use, quality of life and adverse events, (AE)). A pilot design was chosen for the following reasons. First, to assess the feasibility of conducting a sufficiently powered randomized controlled trial in the future. Second, to evaluate the study design and thirdly to calculate a sample size more accurately. We hypothesize that in both patient groups (OA and PPSP), knee pain relief after conventional RF treatment is not inferior to cooled RF. In this article, only the effectivity outcomes will be discussed.

## METHODS

### Trial design

The COCOGEN trial is a prospective, double-blind, randomized, non-inferiority, pilot trial conducted in three participating centers (Hospital Oost-Limburg, Belgium; Maastricht UMC+, The Netherlands; Rijnstate, The Netherlands). Total follow-up time was 6 months. Patients were enrolled from February 10, 2020 to April 28, 2021.

### Randomization, allocation, and blinding

Participants were randomly allocated to one of two parallel groups, conventional or cooled RF, with an allocation ratio of 1:1, and variable block size of 2 or 4 after stratification per etiology of pain (OA and PPSP) using the online CASTOR EDC application. The study was double-blinded: both the patient and the outcome assessor were blinded to treatment allocation. The treating pain physician was unblinded. The blinding of patients was tested approximately 30 min after the treatment by asking the patient which intervention they thought they received with the following possible answers: ‘Conventional RF’, ‘Cooled RF’, and ‘I don’t know’. All patients were systematically unblinded 6 months after treatment.

### Participants

Patients were recruited by their treating pain physician. Adult subjects were included if they suffered from moderate to severe (Numeric Rating Scale (NRS) >4) chronic anterior knee pain (> 12 months) due to OA or PPSP after TKA that was unresponsive to conventional treatments (physiotherapy, analgesics, or intra-articular infiltrations). For OA patients, a radiologic confirmation of Kellgren-Lawrence (KL) grades II–IV on X-ray or MRI was required.<sup>10</sup> For PPSP after TKA patients, a negative orthopedic workout was required.<sup>11</sup> Informed consent was obtained in all patients before participation. Exclusion criteria were: body mass index >40 kg/m<sup>2</sup>; chronic widespread pain;

untreated psychosocial disease; radicular pain in index leg; local or systemic infection (bacteremia); uncontrolled immune suppression; uncontrolled coagulopathy (defined as supratherapeutic dose of anticoagulation medication); currently implanted with a defibrillator, neuromodulator or other electrical devices; allergies to products used during the intervention; evidence of inflammatory arthritis or an inflammatory systemic disease responsible for knee pain; intra-articular injections (eg, steroids, hyaluronic acid, platelet enriched plasma) in the index knee during the 3 months prior to start study; previous conventional or cooled RF of the index knee; pregnant, nursing or planning to become pregnant before the treatment; participation in another clinical trial/investigation within 30 days prior to signing informed consent and patients who refused to comply to protocol procedure.

### Study procedures and data collection

The study data were collected from the medical patient record, questionnaires, and functionality tests at baseline, 1, 3 and 6 months after the procedure in an online patient case report form in the Castor data management tool. Data collection at baseline included: demographic data, NRS, KL grade of OA, results of goniometry, and results of the timed-up-and-go test (TUG). Data collected at the follow-up visits were: NRS, Oxford knee score (OKS), patient’s self-reported impression of change measured by the Patient’s Global Impression of Change (PGIC), health-related quality of life expressed in EuroQol-5 Dimension-3 Level (EQ-5D-3L), mental health measured by Hospital Anxiety and Depression Scale (HADS) and in the Pain Catastrophizing Scale (PCS), medication use measured by the change in Medication Quantification Scale III (MQS III), knee functionality measured using goniometry and the TUG test, and AE. The OKS, HADS, PCS and functionality tests were only collected at the 3-month and 6-month follow-up visit. The NRS score at each time point was calculated as the mean score of the previous 4 days, collected using a pain diary.

### Intervention

An RF treatment of the superomedial, superolateral, and inferomedial genicular nerves was performed in a standardized manner in both treatment groups using a Halyard/Coolief RF generator.<sup>12</sup> A prognostic block prior to the treatment was not performed as a recent study showed no benefit of prior prognostic blocks.<sup>13</sup> All patients were monitored. No sedation was used. Patients were positioned in a supine position on a fluoroscopy table with the index knee flexed 10°–15°. The procedure was performed under sterile conditions. For each nerve, the needle was placed guided by ultrasound in the proximity of the genicular nerve at the junction of the shaft and condyle of the femur and tibia. After identifying the target point, the skin and subcutaneous tissues were anesthetized with 1 mL lidocaine 2% at estimated entry point. The needle was advanced using an anterior to posterior ‘in plane’ approach until contact is made with the bony cortex at the center between anterior and posterior of the femur and tibia. If ultrasound guided needle tip position was final a control fluoroscopy image was made to confirm the final needle tip position in AP and lateral view. A sensory threshold (50 Hz) of ≤0.5V and an absent response to motor stimulation (2 Hz) of 1.0V was obtained for each genicular nerve. Consequently, 1 mL of lidocaine 2% was injected at each genicular nerve before RF treatment. The conventional RF was performed using for each nerve a 100 mm, 18-gage, straight RF introducer and a 10 mm active tip RF probe set at a temperature of 80°C at

the tip for 90s. The cooled RF was performed with a 100 mm long, 17-gage, straight RF introducer and a 4 mm active tip, 18-gage cooled RF probe generating a temperature of 60°C at the tip of the probe for 150s.

## Outcomes

Endpoints were chosen following the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines.<sup>14</sup> The primary endpoint is the proportion of patients with a pain reduction of at least 50% at 3 months postintervention. Pain intensity is expressed using the 11-point NRS. The NRS is a unidimensional, subjective measurement of pain intensity, expressed by the patient as a number between 0 and 10, ranging from no pain to maximal pain. A pain diary containing 3 NRS recordings per day for 4 days prior to each visit during the active hours of the day was collected. The NRS was not specified to be evaluated in rest or in movement, thus aiming to reflect the pain the patient experienced during normal daily activities. We used a threshold of 50% pain decrease, despite the IMMPACT guidelines recommending a threshold of 30%. We chose for 50% as this threshold is most often used in the clinic, as well in previous studies, making comparisons later on easier. In addition, we also collected data on at least 30% pain reduction.

The secondary endpoints were NRS, OKS, PGIC, EQ-5D-3L, HADS, PCS, MQS III, goniometry, TUG test, and AEs.<sup>15-23</sup> PGIC was measured using a 7-point Likert scale ranging from '0' meaning 'Much worse' to 7 meaning 'Extremely improved'. Patients scoring 6 and 7 were considered having a significant improvement. Success of blinding was also tested as mentioned previously.

## Statistical methods

The rule-of-thumb of Julious suggested including 12 patients per group in case of a pilot study, so that preliminary data on effect sizes, measures of spread, and feasibility can be obtained.<sup>24</sup> As this study is stratified by indication (OA and PPSP after TKA), we aimed to include a total of 48 patients.


The clinical outcomes were analyzed according to the intention-to-treat principle. Patient baseline characteristics were described for both knee pain groups separately and stratified by treatment allocation using mean and SD for continuous variables, and count and percentage for categorical variables.

The primary outcome, the proportion of patients achieving treatment success at 3 months after treatment, was computed as percentage and was tested between groups using Pearson's  $\chi^2$  test. To test for non-inferiority, mean NRS change from baseline and between group difference in change score, including 95% CI, were calculated at 3 months. The lower bound of the 95% CI of the difference was compared with the non-inferiority limit of 0.75 NRS points.<sup>25 26</sup> Other secondary study parameters were reported as mean or percentage difference including 95% CI. All hypothesis testing was considered explorative.

## RESULTS

### Participants

Seventy patients were screened for eligibility, of which 49 were included. One additional patient was included due to a small lag in registration in the database as the last two patients were recruited approximately at the same time in different centers. **Figure 1** depicts the Consolidated Standards of Reporting Trials flow chart of participants during the trial. Three patients dropped out, one of which received a TKA. There were further no missing data for the primary endpoint and there were no



**Figure 1** Participant flow chart during the study. All allocated participants received the planned treatment and were analyzed according to the intention-to-treat principle. OA, osteoarthritis; PPSP, persistent postsurgical pain; TKP, total knee prosthesis; RF, radiofrequency.

cross overs between the groups. **Table 1** presents the baseline patient characteristics.

### The primary outcome

There were more patients who achieved the primary endpoint after a cooled RF in comparison with conventional RF as described in **table 2**. Similarly, a higher percentage of patients reached  $\geq 50\%$  pain reduction after a cooled RF in comparison with conventional RF at all other time points. However, these differences were not statistically significant at each time point.

The ORs of  $\geq 50\%$  pain reduction after a cooled versus conventional RF treatment were 1.46 (95% CI 0.44 to 4.87), 2.38 (95% CI 0.60 to 9.38) and 2.7 (95% CI 0.69 to 10.55), respectively at 1, 3 and 6 months after treatment in the whole group, independent of the indication.

The differences between the proportion of patients with  $\geq 50\%$  pain reduction after an RF treatment (conventional and cooled combined) between OA and PPSP were also not statistically significant at each time point, although absolute numbers were at each time point higher in the OA group.

### Secondary outcomes

#### Numerical Rating Scale

At each time point, the mean NRS score of the OA subgroup, PPSP subgroup and the whole population decreased in a

**Table 1** Baseline demographic characteristics of patients per stratification group

	Conventional RF	Cooled RF
<b>OA</b>		
Sample size, n (%)	12 (48)	13 (52)
Sex, n (%)		
Male	1 (8)	7 (54)
Female	11 (92)	6 (46)
Mean age (SD) in years	62.0 (14.4)	62.0 (13.1)
Mean grade of OA (SD)	3.1 (0.8)	3.2 (0.9)
Mean BMI (SD) in kg/m <sup>2</sup>	32.6 (4.9)	29.1 (4.0)
Mean NRS score (SD)	6.4 (1.4)	5.3 (2.1)
Mean OKS score (SD)	16.3 (5.6)	21.5 (7.4)
Mean EQ-5D-3L score (SD)	0.4 (0.29)	0.4 (0.3)
Mean MQS III score (SD)	9.1 (5.9)	8.1 (6.4)
Mean PCS score (SD)	22.6 (13.0)	23.5 (11.8)
Mean HADS depression subscale (SD)	5.6 (3.8)	8.5 (4.8)
Mean HADS anxiety subscale (SD)	6.6 (5.2)	9.1 (5.0)
<b>Goniometry</b>		
Mean knee flexion (SD) in degrees	65.8 (16.8)	69.1 (24.2)
Mean knee extension (SD) in degrees	168.0 (7.7)	162.9 (9.7)
Mean Timed Up-and-Go Test score (SD) in seconds	14.0 (4.8)	14.5 (5.5)
<b>PPSP after TKA</b>		
Sample size, n (%)	12 (50)	12 (50)
Sex, n (%)		
Male	2 (17)	4 (33)
Female	10 (83)	8 (67)
Mean age (SD) in years	65.0 (11.8)	65 (8.8)
Mean BMI (SD) in kg/m <sup>2</sup>	28.8 (5.2)	28.2 (5.6)
Mean NRS score (SD)	6.0 (1.8)	6.9 (1.2)
Mean OKS score (SD)	20.8 (6.5)	17.1 (5.4)
Mean EQ-5D-3L score (SD)	0.4 (0.3)	0.5 (0.34)
Mean MQS III score (SD)	6.3 (6.8)	10.0 (6.5)
Mean PCS score (SD)	24.9 (9.0)	24.1 (9.7)
Mean HADS depression subscale (SD)	8.3 (4.1)	6.1 (5.2)
Mean HADS anxiety subscale (SD)	8.8 (3.2)	7.2 (4.6)
<b>Goniometry</b>		
Mean knee flexion (SD) in degrees	59.4 (16.1)	67.8 (17.5)
Mean knee extension (SD) in degrees	165.2 (9.7)	164.9 (7.3)
Mean timed up-and-go test score (SD) in seconds	14.6 (3.4)	14.8 (3.7)

Values are reported as means (SD) unless specified otherwise. BMI, body mass index; EQ-5D-3L, EuroQol-5 Dimension-3 Level; HADS, Hospital Anxiety and Depression Scale; MQS III, Medication Quantification Scale III; NRS, Numerical Rating Scale; OA, osteoarthritis; OKS, Oxford Knee Score; PCS, Pain Catastrophizing Scale; PPSP, persistent postsurgical pain; TKA, total knee arthroplasty.

statistically significant manner ( $p < 0.05$ ) compared with baseline after both conventional and cooled RF treatment (figure 2). The mean pain reduction ( $\Delta$ NRS) (95% CI) at 3 months compared with baseline was  $-2.0$  ( $-3.2$  to  $-0.9$ ) for OA,  $-2.0$  ( $-2.8$  to  $-1.1$ ) for PPSP and  $-2.0$  ( $-2.7$  to  $-1.3$ ) for the whole population. In patients treated with cooled RF, the mean pain reduction ( $\Delta$ NRS) (95% CI) at 3 months compared with baseline was  $-2.2$  ( $-4.2$  to  $-0.1$ ) for OA,  $-2.5$  ( $-3.8$  to  $-1.2$ ) for PPSP and  $-2.3$  ( $-3.5$  to  $-1.2$ ) for the whole population. In patients treated with conventional RF, the mean pain reduction ( $\Delta$ NRS) (95% CI) at 3 months compared with baseline was  $-1.9$  ( $-3.3$  to  $-0.5$ ) for OA,  $-1.5$  ( $-2.6$  to  $-0.3$ ) for PPSP and  $-1.7$  ( $-2.5$  to  $-0.8$ ) for the whole population. The mean  $\Delta$ NRS of the OA and PPSP subgroup was statistically significant at each follow-up point compared with baseline, but the mean  $\Delta$ NRS was not significantly different between the OA and PPSP subgroups at each

follow-up moment. When analyzing both the OA and PPSP population together, at each follow-up point, the  $\Delta$ NRS of cooled RF compared with baseline was not significantly different to the  $\Delta$ NRS of conventional RF compared with baseline. There was, however, an increase of the  $\Delta$ NRS over time in the whole cooled RF group compared with a decrease in the whole conventional RF group.

### The non-inferiority outcome

The non-inferiority comparison between conventional and cooled RF was performed on the combined OA and PPSP population due to the limited number of patients included in this trial. The point estimate difference in NRS was 1 at 3 months but as the 95% CI ( $-0.6$  to  $2.7$ ) includes the non-inferiority margin of 0.75, it is inconclusive at this point (figure 3).

### Patient's Global Impression of Change, OKS, EQ-5D-3L, HADS, PCS, MQSIII, Goniometry, and TUG test.

Table 3 describes the evolution of the secondary outcomes at different time points compared between conventional and cooled RF treatment of the genicular nerves in the whole population.

### Adverse events

There were no serious AE. There were no significant differences in prevalence of AE between conventional and cooled RF, respectively, 5 and 6 cases. After conventional RF, five patients reported a transient increase in pain. After cooled RF, three patients developed a subcutaneous hematoma which resolved spontaneously, one patient developed infrapatellar hypoesthesia, and two patients reported a transient increase in pain.

### Blinding

Data from two participants were missing. Thirty-nine patients (83%) reported that they did not know which treatment they received. Five patients (11%) guessed the wrong allocation and three (6%) guessed right.

## DISCUSSION

As this is a pilot trial with inherent low statistical power, the primary goal was to estimate and compare the treatment effect size of conventional and cooled RF of the genicular nerves. This study showed that the proportion of patients with at least 50% pain reduction was higher, although not significantly, after a cooled RF treatment of the genicular nerves in comparison with a conventional RF treatment in patients with chronic knee pain due to OA, PPSP and the whole population at each time point up to 6 months after the procedure. Mainly, in the PPSP group cooled RF led to higher proportion of patients with  $\geq 50\%$  pain reduction in comparison with conventional RF. The differences were not statistically significant reflecting among others the insufficient sample size of this pilot trial. Despite this, we found a statistically significant pain reduction after both conventional and cooled RF treatment of the genicular nerves up to 6 months postprocedure. The point estimate of the difference in mean pain reduction from baseline between conventional and cooled RF at 3 months was one which could indicate inferiority of conventional RF, nevertheless, these results are inconclusive as the 95% CI included the non-inferiority margin of 0.75. At 6 months, the mean pain reduction of the patients treated with cooled RF was 2.5 point, which is above the clinically relevant margin of 2 points according to the IMMPACT guidelines. This was not the case with conventional RF. The proportion of patients with  $\geq 50\%$  pain reduction and the absolute pain

**Table 2** Percentage of patients with  $\geq 30\%$  and  $\geq 50\%$  pain reduction after conventional and cooled RF treatment

	OA			PPSP			Whole group		
	Conv RF, n (%)	Cooled RF, n (%)	P value* †	Conv RF, n (%)	Cooled RF, n (%)	P value† ‡	Conv RF, n (%)	Cooled RF, n (%)	P value† §
$\geq 50\%$ pain reduction compared with baseline									
1 month	5/12 (41.7)	6/12 (50)	1.00	2/12 (16.7)	3/12 (25)	1.00	7/24 (29.2)	9/24 (37.5)	0.54
3 months	3/12 (25)	4/12 (33.3)	1.00	1/11 (9.1)	4/12 (33.3)	0.32	4/23 (17.4)	8/24 (33.3)	0.21
6 months	3/11 (27.3)	4/12 (33.3)	1.00	1/11 (9.1)	5/12 (41.7)	0.16	4/22 (18.2)	9/24 (37.5)	0.15
$\geq 30\%$ pain reduction compared with baseline									
1 month	6/12 (50)	7/12 (58.3)	0.68	4/12 (33.3)	6/12 (50)	0.41	10/24 (41.7)	13/24 (54.2)	0.39
3 months	5/12 (41.7)	8/12 (66.7)	0.22	2/11 (18.2)	6/12 (50)	0.19	7/23 (30.4)	14/24 (58.3)	0.05
6 months	4/11 (36.4)	5/12 (41.7)	1.00	1/11 (9.1)	5/12 (41.7)	0.16	5/22 (22.7)	10/24 (41.7)	0.17

\*P value compares conventional RF versus cooled RF procedure in the OA group.

†Pearson's  $\chi^2$  test used to compare proportions.

‡P value compares conventional RF versus cooled RF procedure in the PPSP group.

§P value compares conventional RF versus cooled RF procedure in the whole population.


OA, osteoarthritis; PPSP, persistent postsurgical pain; RF, radiofrequency ablation.

reduction, although both higher in the OA group, did not differ statistically significant between OA or PPSP. Most secondary outcomes improved in time after both conventional and cooled RF. We found no statistically significant difference in secondary outcomes between both RF treatments. There were no serious AE reported, indicating that both RF modalities are safe. Results of the blinding analysis also indicate that the blinding process was adequate. In a large retrospective study by Kapural *et al* cooled RF also resulted in a higher chance of treatment success and a longer duration of effect in comparison with conventional RF in OA patients.<sup>27</sup>

When comparing the findings of this trial with the literature, we remark that treatment success in this study is lower. Earlier studies demonstrate treatment success (proportion  $\geq 50\%$  pain reduction) of a conventional RF between 32% and 59% at 3 months and after a cooled RF between 61% and 74% at 6 months.<sup>12 13 28 29</sup> First, this difference could be explained by the fact that no prognostic block was used in this trial. We did not include a prognostic block as we considered that its possible benefit did not outweigh the risks. The possible benefit is a better patient selection and by this better treatment outcomes. However, the randomized controlled trial by McCormick *et al* showed that a prognostic block with 1 mL of local anesthetic and a 50% threshold did not lead to improved pain and knee function outcomes in comparison with not performing a prognostic

block.<sup>13</sup> At the moment, there are no prospective studies showing a better outcome with the use of prognostic genicular nerves blocks prior to RF. The main drawback of using prognostic blocks, is that patients with a false-negative block are refused a potentially safe and effective treatment. Furthermore, there are also other downsides and risks associated with the use of prognostic blocks such as an increased cost, patient discomfort and especially in the group of patients post-TKA the risk of infection. Moody *et al* reported two cases of patients with PPSP suffering a knee infection after a prognostic genicular nerve block.<sup>30</sup> Also, there are other studies where investigators have decided to not perform a prognostic block.<sup>31–33</sup> Second, most published studies include only OA patients, whereas in this study both OA and PPSP patients were included. To our knowledge, this is the first RCT that investigated the effects of cooled RF in PPSP patients. In operated patients, anatomy can be even more variable and causes of pain can be plural resulting in diminished treatment success. As this study found an effect size of the primary endpoint of 18.7% and 37.5%, respectively, for conventional and cooled RF at 6 months in the whole population, it is of utmost importance that future studies also include a sham procedure to evaluate the possible placebo effect.

The prevalence of knee OA is rising and subsequently also the prevalence of total knee replacement and that of PPSP after TKA. As these conditions have a high impact on the patients'

**Figure 2** Mean NRS at each time point compared between conventional and cooled RF in the whole group.

Non-inferiority graphic of the COCOGEN trial  
Point estimate +1 with 95% CI of -0.6 to 2.7




Figure 3 Non-inferiority graphic. RF, radiofrequency ablation.

health-related quality of life and a high societal cost, there is a need for minimally invasive alternative treatments.<sup>27</sup> As cooled RF is associated with a higher product cost it is important to determine not only its effectiveness but also the cost-effectiveness.<sup>34</sup>

This study has several limitations. First, as this is a pilot trial sample size is, inherent to the design, too low to draw conclusions. Nevertheless, as this is the first trial to directly compare conventional and cooled RF of the genicular nerves in an RCT, results remain important to guide future research. Second, there was no prognostic block used prior to the RF treatment in both OA and PPSp patients which could have influenced our results. Third, this study was designed to target only three genicular nerves. In the literature, there is an ongoing discussion on possible strategies to increase treatment success, for example, by targeting more nerves or targeting nerves at different locations as cadaveric studies demonstrate significant anatomical variability.<sup>35 36</sup> Fonkoue *et al* performed a study that compared an injection of 5 vs 3 nerves with LA and steroid in OA patients with a follow-up of 12 months.<sup>37</sup> They found in both groups a significant reduction in pain intensity but only a significant greater pain reduction in the group with 5 nerves 1-hour post-operative. All the other time points showed no significant difference. Furthermore, the study performed by Chen *et al* targeted four nerves with cooled RF and found that 71% of patients report  $\geq 50\%$  pain reduction at 6 months.<sup>38</sup> These results are comparable (74.1% of patients reported  $\geq 50\%$  pain reduction) with the study of Davis *et al* with a similar design with the exception that they only targeted three genicular nerves.<sup>39</sup> The retrospective analysis of Chen *et al* found that targeting more than three nerves increased treatment success (Global Perceived Effect  $>30\%$ ) from 57.5% (126/219) to 80% (36/45), although there are inherent limitations due to the retrospective design.<sup>40</sup> The editorial of Kim and Cohen advocates that ablation of up to ten genicular nerves could improve outcomes of this treatment.<sup>36</sup> However, this hypothesis is also based in *ex vivo* studies and prospective clinical trials on patients comparing the number of genicular nerves targeted are lacking. It is at this time unknown whether denervation of all nerves, which innervate the anterior knee, is necessary for adequate analgesia.<sup>36</sup> On the other hand, increasing the number of lesions, also increase the risk of complications, therefore each intervention should be a balance between possible clinical benefits and risk of complications. At the time this study was conducted, most studies performed an RF treatment of the genicular nerves on three nerves. Nevertheless, targeting more than three nerves theoretically could lead to better outcomes and should be focus of future research.

Table 3 The evolution of secondary outcomes at different time points compared between conventional and cooled RF treatment of the genicular nerves

	Baseline		1-month FU		3 months FU		6 months FU		P value* †
	Conv. RF	Cooled RF	Conv. RF	Cooled RF	Conv. RF	Cooled RF	Conv. RF	Cooled RF	
Mean NRS (SD)	6.2 (1.6)	6.1 (1.8)	4.4 (2.5)	4.1 (2.3)	4.7 (2.2)	3.7 (2.3)	5.0 (2.2)	3.6 (2.2)	0.13‡
Patients with significant improvement in PGIC, n (%)	124/24	125/25	824 (33.3)	111/24 (45.8)	923 (39.1)	1074 (45.5)	522 (22.7)	924 (37.5)	0.28
Mean OKS score (SD)	18.1 (6.1)	19.8 (7.2)	-	-	26.3 (9.1)	28.9 (9.6)	25.0 (9.6)	27.0 (8.7)	0.47
Mean EQ-5D-3L score (SD)	0.4 (0.3)	0.5 (0.3)	0.6 (0.3)	0.6 (0.3)	0.6 (0.3)	0.6 (0.2)	0.6 (0.3)	0.6 (0.28)	0.62
Mean HADS depression subscale (SD)	7.0 (4.2)	7.0 (5.2)	-	-	6.2 (5.2)	5.1 (5.1)	7.0 (4.9)	5.46 (4.8)	0.31
Mean HADS fear subscale (SD)	7.7 (4.5)	8.0 (4.8)	-	-	6.1 (4.4)	5.27 (3.7)	6.38 (4.6)	6.0 (4.7)	0.79
Mean PCS score (SD)	24.2 (11.0)	23.5 (10.9)	-	-	22.2 (12.5)	18.1 (11.4)	23.1 (13.7)	18.0 (12.4)	0.20
Mean MQS III score (SD)	7.7 (6.4)	9.1 (6.4)	9.3 (6.0)	9.2 (5.6)	8.8 (6.2)	5.2 (4.5)	5.0 (5.2)	6.2 (5.0)	0.40
Goniometry: Mean knee Flexion (SD) in degrees	62.5 (16.6)	62.5 (16.6)	-	-	68.4 (7.2)	68.4 (7.2)	68.4 (7.2)	64.9 (17.3)	0.91
Goniometry: Mean knee Extension (SD) in degrees	167.1 (8.7)	152.7 (32.2)	-	-	168.4 (7.2)	166.8 (12.3)	169.1 (6.3)	165.1 (11.6)	0.18
Timed Up-and-Go Test score (SD) in seconds	14.1 (4.2)	14.6 (4.7)	-	-	13.9 (7.2)	12.0 (3.9)	11.8 (5.5)	10.9 (2.8)	0.49

\* P value compares conventional RF versus cooled RF procedure.

† Pearson's  $\chi^2$  test used to compare proportions and paired t-test used to compare means.

‡ P value of mean paired difference between baseline and follow-up NRS.

Conv, conventional; EQ-5D-3L, EuroQol-5 Dimension-3 Level; HADS, Hospital Anxiety and Depression Scale; MQS III, Medication Quantification Scale III; NRS, Numeric Rating Scale; OA, osteoarthritis; OKS, Oxford Knee Score; PCS, Pain Catastrophizing Scale; PGIC, Patient's Global Impression of Change; PPSp, persistent postsurgical pain; RF, radiofrequency ablation; TKa, total knee arthroplasty.

## CONCLUSIONS

In conclusion, both conventional and cooled RF of the genicular nerves reduced pain in the OA and PPSP population. The explorative results of this pilot study showed that a not statistically significant higher proportion of patient experienced  $\geq 50\%$  pain reduction from baseline after cooled RF compared with conventional RF. The non-inferiority analysis was inconclusive. Further research in the form of a powered comparative RCT is warranted.

## Author affiliations

<sup>1</sup>Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Multidisciplinary Pain Center, Ziekenhuis Oost-Limburg, Genk, Belgium

<sup>2</sup>Department of Anesthesiology and Pain Medicine, Maastricht UMC+, Maastricht, The Netherlands

<sup>3</sup>Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium

<sup>4</sup>Department of Anesthesiology and Pain Medicine, Rijnstate, Arnhem, The Netherlands

<sup>5</sup>Department of Clinical Epidemiology & Medical Technology Assessment, Maastricht UMC+, Maastricht, The Netherlands

<sup>6</sup>Department of Orthopaedic Surgery, CAPHRI School for Public Health and Primary Care, Maastricht UMC+, Maastricht, The Netherlands

<sup>7</sup>Department of Orthopedic Surgery, Ziekenhuis Oost-Limburg, Genk, Belgium

<sup>8</sup>GRIT Belgian sports clinic, Leuven, Belgium

<sup>9</sup>Department of Rehabilitation Sciences and Physiotherapy, BIOMED REVAL Rehabilitation Research Institute, Hasselt University, Hasselt, Belgium

**Acknowledgements** The authors wish to thank Nelleke De Meij and Philma Beijers for their assistance in coordination and patient data gathering for the COCOGEN study.

**Contributors** All authors have contributed substantially to the manuscript and agree with the content. Thibaut Vanneste acts as guarantor of overall content.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Ethics approval was granted from the ethical committees of Hospital Oost-Limburg (19/0038U) and Maastricht UMC+ (NL69877.068.19/METC 19-031). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Thibaut Vanneste <http://orcid.org/0000-0002-1920-8085>

Amy Belba <http://orcid.org/0000-0002-9422-8940>

Jan Van Zundert <http://orcid.org/0000-0002-5389-2036>

## REFERENCES

- Safiri S, Kolahi A-A, Smith E, *et al*. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. *Ann Rheum Dis* 2020;79:819-28.
- Ng M, Fleming T, Robinson M, *et al*. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. *Lancet* 2014;384:766-81.

- Weinstein AM, Rome BN, Reichmann WM, *et al*. Estimating the burden of total knee replacement in the United States. *J Bone Joint Surg Am* 2013;95:385-92.
- Liu SS, Buvanendran A, Rathmell JP, *et al*. A cross-sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. *Reg Anesth Pain Med* 2012;37:415-22.
- Wylde V, Beswick A, Bruce J, *et al*. Chronic pain after total knee arthroplasty. *EFORT Open Rev* 2018;3:461-70.
- Ajrawat P, Radomski L, Bhatia A, *et al*. Radiofrequency procedures for the treatment of symptomatic knee osteoarthritis: a systematic review. *Pain Med* 2020;21:333.
- Chen AF, Mullen K, Casambre F, *et al*. Thermal nerve radiofrequency ablation for the nonsurgical treatment of knee osteoarthritis: a systematic literature review. *J Am Acad Orthop Surg* 2021;29:387-96.
- Meiling JB, Barndt BS, Ha CT, *et al*. The therapeutic effect of genicular nerve radiofrequency for chronic knee pain after a total knee arthroplasty: a systematic review. *Interventional Pain Medicine* 2022;1:100072.
- McCormick ZL, Korn M, Reddy R, *et al*. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to knee osteoarthritis: six-month outcomes. *Pain Med* 2017;18:1631-41.
- Kohn MD, Sassoon AA, Fernando ND. Classifications in brief: kellgren-lawrence classification of osteoarthritis. *Clin Orthop Relat Res* 2016;474:1886-93.
- Hagedorn JM, Wooster BM, Hunt CL, *et al*. Beyond revision surgery: work-up and interventional treatments for the painful total knee arthroplasty. *Pain Pract* 2020;20:929-36.
- Choi W-J, Hwang S-J, Song J-G, *et al*. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *Pain* 2011;152:481-7.
- McCormick ZL, Reddy R, Korn M, *et al*. A prospective randomized trial of prognostic genicular nerve blocks to determine the predictive value for the outcome of cooled radiofrequency ablation for chronic knee pain due to osteoarthritis. *Pain Med* 2018;19:1628-38.
- Turk DC, Dworkin RH, Allen RR, *et al*. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2003;106:337-45.
- Collins NJ, Misra D, Felson DT, *et al*. Measures of knee function: International Knee Documentation Committee (IKDC) subjective knee evaluation form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). *Arthritis Care Res* 2011;63:5208-28.
- Steffen TM, Hacker TA, Mollinger L, Age- ML. Age- and gender-related test performance in community-dwelling elderly people: six-minute walk test, berg balance scale, timed up & go test, and gait speeds. *Phys Ther* 2002;82:128-37.
- Bilbao A, Garcia-Pérez L, Arenaza JC, *et al*. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. *Qual Life Res* 2018;27:2897-908.
- Smarr KL, Keefer AL. Measures of depression and depressive symptoms. *Arthritis Care Res* 2020;72:608-29.
- Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. *J Pain* 2009;10:573.
- Ikemoto T, Hayashi K, Shiro Y, *et al*. A systematic review of cross-cultural validation of the pain catastrophizing scale. *Eur J Pain* 2020;24:1228-41.
- Haefeli M, Elfering A. Pain assessment. *Eur Spine J* 2006;15 Suppl 1:S17-24.
- Gallizzi M, Gagnon C, Harden RN, *et al*. Medication quantification scale version III: internal validation of detriment weights using a chronic pain population. *Pain Pract* 2008;8:1-4.
- Hancock GE, Hepworth T, Wembridge K. Accuracy and reliability of knee goniometry methods. *J Exp Orthop* 2018;5:46.
- Julius SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat* 2005;4:287-91.
- Kagelidou F, Le Roux E, Mangiarini L, *et al*. Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol. *BMJ Open* 2019;9:e023296.
- Voepel-Lewis T, Burke CN, Jeffreys N, *et al*. Do 0-10 numeric rating scores translate into clinically meaningful pain measures for children? *Anesth Analg* 2011;112:415-21.
- Kapur L, Minerali A, Sanders M, *et al*. Cooled radiofrequency ablation provides prolonged pain relief compared to traditional radiofrequency ablation: a real-world, large retrospective clinical comparison from a single practice. *J Pain Res* 2022;15:2577-86.
- Desai M, Bentley A, Keck WA, *et al*. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data. *BMC Musculoskelet Disord* 2019;20:302.
- Belba A, Vanneste T, Van Kuijk SMJ, *et al*. A retrospective study on patients with chronic knee pain treated with ultrasound-guided radiofrequency of the genicular nerves (Recorgen trial). *Pain Pract* 2022;22:340-8.
- Moody PW, Fehring TK, Springer BD. Periarthicular needle-based therapies can cause periprosthetic knee infections. *Arthroplast Today* 2020;6:241-5.

- 31 Sari S, Aydin ON, Turan Y, *et al.* Which one is more effective for the clinical treatment of chronic pain in knee osteoarthritis: radiofrequency neurotomy of the genicular nerves or intra-articular injection? *Int J Rheum Dis* 2018;21:1772–8.
- 32 Qudsi-Sinclair S, Borrás-Rubio E, Abellan-Guillén JF, *et al.* A comparison of genicular nerve treatment using either radiofrequency or analgesic block with corticosteroid for pain after a total knee arthroplasty: a double-blind, randomized clinical study. *Pain Pract* 2017;17:578–88.
- 33 El-Hakeim EH, Elawamy A, Kamel EZ, *et al.* Fluoroscopic guided radiofrequency of genicular nerves for pain alleviation in chronic knee osteoarthritis: a single-blind randomized controlled trial. *Pain Physician* 2018;21:169–77.
- 34 Kolasinski SL, Neogi T, Hochberg MC, *et al.* 2019 American college of rheumatology/ arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Rheumatol* 2020;72:220–33.
- 35 Fonkoue L, Stoenoiu MS, Behets CW, *et al.* Validation of a new protocol for ultrasound-guided genicular nerve radiofrequency ablation with accurate anatomical targets: cadaveric study. *Reg Anesth Pain Med* 2021;46:210–6.
- 36 Kim PY, Cohen SP. Genicular nerve blocks and radiofrequency ablation for knee osteoarthritis: more nerves, more questions. *Pain Med* 2021;22:1019–21.
- 37 Fonkoue L, Steyaert A, Kouame J-EK, *et al.* A comparison of genicular nerve blockade with corticosteroids using either classical anatomical targets vs revised targets for pain and function in knee osteoarthritis: a double-blind, randomized controlled trial. *Pain Med* 2021;22:1116–26.
- 38 Chen AF, Khalouf F, Zora K, *et al.* Cooled radiofrequency ablation compared with a single injection of hyaluronic acid for chronic knee pain: a multicenter, randomized clinical trial demonstrating greater efficacy and equivalent safety for cooled radiofrequency ablation. *J Bone Joint Surg Am* 2020;102:1501.
- 39 Davis T, Loudermilk E, DePalma M, *et al.* Prospective, multicenter, randomized, crossover clinical trial comparing the safety and effectiveness of cooled radiofrequency ablation with corticosteroid injection in the management of knee pain from osteoarthritis. *Reg Anesth Pain Med* 2018;43:84–91.
- 40 Chen Y, Vu T-NH, Chinchilli VM, *et al.* Clinical and technical factors associated with knee radiofrequency ablation outcomes: a multicenter analysis. *Reg Anesth Pain Med* 2021;46:298–304.

NL69877.068.19

Cocogen Trial

Comparison of **cooled** versus **conventional** radiofrequency treatment of the **genicular** nerves for chronic knee pain: a multicentre randomised controlled non-inferiority pilot trial  
(Cocogen trial)  
(**January 2021**)

NL69877.068.19

Cocogen Trial

**PROTOCOL TITLE:** Comparison of cooled versus conventional radiofrequency treatment of the genicular nerves for chronic knee pain: a multicentre randomised controlled non-inferiority pilot trial

<b>Protocol ID</b>	<b>NCT03865849</b>
<b>Short title</b>	<b>Cocogen Trial</b>
<b>Version</b>	<b>7.0</b>
<b>Date</b>	<b>25-01-2021</b>
<b>Coordinating investigator / project leader</b>	<b>Prof. dr. Jan van Zundert, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Hospital Oost - Limburg, Genk, Belgium. +32(0)89325254 Department of Pain Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands.</b>
<b>Principal investigator(s)</b>	<b>- Drs. Thibaut Vanneste, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Hospital Oost - Limburg, Genk, Belgium. +32(0)89325316</b>  <b>- Drs. Jan Willem Kallewaard, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Rijnstate, Arnhem, the Netherlands. +31(0)622412029</b>  <b>- Dr. Micha Sommer, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands. +31(0)647268700</b>
<b>Sponsor</b>	<b>azM</b>
<b>Subsidising party</b>	<b>/</b>
<b>Independent expert</b>	<b>- Dr. Pieter Emans, Orthopaedic Surgeon Department of Orthopaedics, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands. +31(0)433875039</b>  <b>Dr. Roel Mestrum, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Regional Hospital Tienen, Belgium. +32(0)16809028</b>

NL69877.068.19

Cocogen Trial

## PROTOCOL SIGNATURE SHEET

Name	Signature	Date
<b>Head of department:</b>  Prof. dr. Jan van Zundert, Anaesthesiologist Department of Pain Medicine, Maastricht University Medical Centre (MUMC+) Maastricht, the Netherlands		
<b>Principal Investigator:</b>  - Drs. Thibaut Vanneste, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Hospital Oost - Limburg Genk, Belgium +32(0)89325316  - Drs. Jan Willem Kallewaard, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Rijnstate Arnhem, the Netherlands +31(0)622412029  - Dr. Micha Sommer, Anaesthesiologist Department of Anaesthesiology / Pain Medicine, Maastricht University Medical Centre (MUMC+) Maastricht, the Netherlands +31(0)647268700	  	

NL69877.068.19

Cocogen Trial

**TABLE OF CONTENTS**

<b>1. INTRODUCTION AND RATIONALE</b>	10
<b>2. OBJECTIVES</b>	11
<b>3. STUDY DESIGN</b>	12
<b>4. STUDY POPULATION</b>	14
4.1 Population (base)	14
4.2 Inclusion criteria	14
4.3 Exclusion criteria	14
4.4 Sample size calculation	15
<b>5. TREATMENT OF SUBJECTS</b>	15
5.1 Investigational treatment	16
5.2 Use of co-intervention	19
5.3 Escape medication	19
<b>6. NON-INVESTIGATIONAL PRODUCT</b>	19
6.1 Name and description of non-investigational product(s)	20
6.2 Summary of findings from clinical studies	21
6.3 Preparation and labelling of Non Investigational Medicinal Product	21
<b>7. METHODS</b>	22
7.1 Study parameters/endpoints	22
7.1.1 Main study parameters/endpoints	22
7.1.2 Secondary study parameters/endpoints	22
7.1.3 Other study parameters	24
7.2 Randomisation, blinding and treatment allocation	24
7.3 Study procedures	25
7.4 Withdrawal of individual subjects	25
7.5 Premature termination of the study	25
<b>8. SAFETY REPORTING</b>	25
8.1 Temporary halt for reasons of subject safety	27
8.2 AEs, SAEs and SUSARs	27
8.2.1 Adverse events (AEs)	27
8.2.2 Serious adverse events (SAEs)	28
8.2.3 Suspected unexpected serious adverse reactions (SUSARs)	29
8.3 Annual safety report	29
8.4 Follow-up of adverse events	29
8.5 Safety Committee	29
<b>9. STATISTICAL ANALYSIS</b>	29
9.1 Primary study parameter(s)	30
9.2 Secondary study parameter(s)	30
9.3 Other study parameters	31
<b>10. ETHICAL CONSIDERATIONS</b>	32
	4

<b>NL69877.068.19</b>	<b>Cocogen Trial</b>
10.1 Regulation statement	32
10.2 Recruitment and consent	32
10.3 Objection by minors or incapacitated subjects (if applicable)	32
10.4 Benefits and risks assessment, group relatedness	32
10.5 Compensation for injury	33
10.6 Incentives	33
<b>11. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION</b>	<b>33</b>
11.1 Handling and storage of data and documents	34
11.2 Amendments	34
11.3 Annual progress report	34
11.4 Temporary halt and (prematurely) end of study report	34
11.5 Public disclosure and publication policy	35
<b>12. REFERENCES</b>	<b>36</b>
<b>13. APPENDIX.</b>	<b>40</b>
Appendix A	40
Appendix B	40
Appendix C	40
Appendix D	40
Appendix E	40

NL69877.068.19

Cocogen Trial

**LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS**

<b>AE</b>	<b>Adverse Event</b>
<b>ALEA</b>	<b>Trans European Network for Clinical Trials Services</b>
<b>AP</b>	<b>Anterior posterior</b>
<b>AR</b>	<b>Adverse Reaction</b>
<b>ASRA</b>	<b>American Society of Regional Anesthesia and Pain Medicine</b>
<b>BMI</b>	<b>Body mass index</b>
<b>CEA</b>	<b>Cost Effectiveness analysis</b>
<b>DSMB</b>	<b>Data Safety Monitoring Board</b>
<b>EQ-5D-5L</b>	<b>EuroQol 5 dimensions 5 level questionnaire</b>
<b>ESA</b>	<b>European society of Anaesthesiology</b>
<b>EU</b>	<b>European Union</b>
<b>FDA</b>	<b>Food and drug administration</b>
<b>GPE</b>	<b>Global perceived effect</b>
<b>HADS</b>	<b>Hospital Anxiety and Depression scale</b>
<b>HRQOL</b>	<b>Health Related Quality of Life</b>
<b>IC</b>	<b>Informed Consent</b>
<b>IL</b>	<b>Inferolateral</b>
<b>IM</b>	<b>Inferomedial</b>
<b>IMMPACT</b>	<b>Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials</b>
<b>IMTA</b>	<b>Institute for medical technology assessment</b>
<b>IRB</b>	<b>Institutional Review Board</b>
<b>METC</b>	<b>Medical research ethics committee (MREC); in Dutch: medisch-ethische toetsingscommissie (METC)</b>
<b>MQS</b>	<b>Medication Quantification Scale</b>
<b>NRS</b>	<b>Numeric Rating Scale</b>
<b>NSAID</b>	<b>Non-steroidal anti-inflammatory drugs</b>
<b>OA</b>	<b>Osteoarthritis</b>
<b>OKS</b>	<b>Oxford Knee Score</b>
<b>PCS</b>	<b>Pain Catastrophizing Scale</b>
<b>PGIC</b>	<b>Patient Global Impression of Change</b>
<b>QALY</b>	<b>Quality- adjusted Life Year</b>
<b>RCT</b>	<b>Randomized controlled trial</b>
<b>RF</b>	<b>Radiofrequency</b>

NL69877.068.19

Cocogen Trial

---

<b>(S)AE</b>	<b>(Serious) Adverse Event</b>
<b>SM</b>	<b>Superomedial</b>
<b>Sponsor</b>	<b>The sponsor is the party that commissions the organisation or performance of the research, for example a pharmaceutical company, academic hospital, scientific organisation or investigator. A party that provides funding for a study but does not commission it is not regarded as the sponsor, but referred to as a subsidising party.</b>
<b>SUSAR</b>	<b>Suspected Unexpected Serious Adverse Reaction</b>
<b>TKA</b>	<b>Total knee arthroplasty</b>
<b>VAS</b>	<b>Visual analogue scale</b>
<b>WMO</b>	<b>Medical Research Involving Human Subjects Act; in Dutch: Wet Medisch-wetenschappelijk Onderzoek met Mensen</b>

NL69877.068.19

Cocogen Trial

**SUMMARY**

**Rationale:** Knee osteoarthritis is a progressive degenerative process that affects joint cartilage and the subchondral bone. Approximately 10% to 30% of all osteoarthritis patients suffer from disabling symptoms such as pain, stiffness and loss of function leading to psychological and sleeping disorders and a diminished quality of life. (1-4) When conservative treatment fails to treat the symptoms, a total knee arthroplasty can be performed. (3, 6-9) Due to comorbidities or young age due to the limited lifetime of the prostheses used, the total knee arthroplasty procedure is not suitable for all patients. Also, persistent pain after a total knee arthroplasty is also possible. For these specific groups of patients a radiofrequent treatment of the genicular nerves (superolateral, superomedial and inferomedial) might be an alternative treatment option. Multiple researchers investigated the effect of conventional and later also, cooled radiofrequent treatment of the genicular nerves, with promising results for both techniques. (20-23) However, the techniques have never been compared in a randomised controlled trial.

**Objective:** The primary goal of this study is to provide an estimate of treatment effects, inclusion rate, and comparability of patients between hospitals to assess the feasibility of conducting a future randomised controlled non-inferiority trial to assess whether the effect of conventional RF treatment of the genicular nerves (superomedial, superolateral and inferomedial) of the index knee on knee pain relief is not inferior to the more expensive cooled RF treatment of the genicular nerves. A secondary goal is to estimate the initial costs and cost-effectiveness of conventional RF treatment compared to cooled radiofrequent treatment so as to determine the need, focus and scope of an economic evaluation alongside the RCT.

**Study design** This study is a prospective, multicentre, double blind, randomised controlled, non-inferiority pilot study.

**Study population:** Adult patients (> 18 years) with chronic, moderate to severe knee pain (NRS>4) due to osteoarthritis, radiological diagnosed to be graded 2-4 according to the Kellgren-Lawrence criteria on Rx or MRI or with persistent postoperative moderate to severe knee pain (NRS>4) after total knee arthroplasty.

**Intervention (if applicable):** One group is treated with a conventional radiofrequent treatment of the genicular nerves (SL, SM, IM) of the index knee. The other group is treated with a cooled radiofrequent treatment.

**Main study parameters/endpoints:** The primary study outcome parameter is the proportion of patients with a pain intensity reduction of at least 50% at 3 months post intervention compared to baseline. Pain intensity is measured by a Numeric Rating Scale. Secondary parameters include physical functioning, health-related quality of life, emotional outcome, patient satisfaction, side effects, duration effect, medication use, costs and cost

**NL69877.068.19****Cocogen Trial**

effectiveness. Inclusion rates per patient subgroup (osteoarthritis and post total knee arthroplasty) and per hospital will be monitored as well.

**Nature and extent of the burden and risks associated with participation, benefit and group relatedness:** After study enrolment and baseline intake, patients are treated and followed at 1, 3, 6 and 12 months after the initial intervention (total of 4 site visits, 1 online visit). Primary endpoint is 3 months post intervention. During the intake a physical examination is done. The treatment itself is performed without sedation and is generally well tolerated without side effects or complications. This study compares two active treatment therapies. Therefore, it is expected that patients from both treatment groups experience similar positive effects regarding pain relief and improved knee function.

NL69877.068.19

Cocogen Trial

## 1. INTRODUCTION AND RATIONALE

Osteoarthritis is one of the most prevalent chronic diseases and a leading cause of pain and disability. (1) The prevalence of radiographic evidence of knee osteoarthritis in persons older than 55 years varies, depending on which study, between 33 and 68%. Approximately 10% to 30% of those have significant pain and functional impairment. (2) Osteoarthritis is a progressive degenerative process that affects joint cartilage and the subchondral bone. The most important symptoms of knee osteoarthritis are pain, stiffness and loss of function leading to psychological and sleeping disorders and a diminished quality of life. (3, 4)

Treatment options can be divided into non-pharmacological, pharmacological, infiltrations and surgical. Non-pharmacological treatments consists of self-management, lifestyle changes, braces, transcutaneous electrical nerve stimulation, acupuncture and physiotherapy. Pharmacological therapy includes oral analgesics like paracetamol and non-steroidal anti-inflammatory drugs (NSAID). Patients that are unresponsive to these analgesics are sometimes prescribed strong opioids, although this should be reserved for exceptional cases due to increasing complications related to (ab)use of opioids. (5) Furthermore minimally invasive measurements such as intra articular injections of steroids or viscosupplementation could also provide short term relief. Unfortunately, conservative treatment is often insufficient or associated with side effects. If this is the case, total knee arthroplasty (TKA) can be performed. (3, 6-9)

TKA is not a guarantee of success given that the incidence of postoperative pain and functional limitation can raise as high as 53%. (10-16) Also, there is a group of patients that is not suitable to undergo surgery due to comorbidities or very young age due to the limited lifetime of the prostheses used. In those groups of patients radiofrequent (RF) treatment of the genicular nerves might be an alternative treatment option.

The sensory innervation of the anterior part of the knee is accomplished by articular branches of the femoral, saphenous, obturator, common peroneal, tibial and sciatic nerve. (17-19) Some of these articular branches are called the genicular nerves. Radiofrequent treatment of the genicular nerves is first described by Choi and colleagues in 2011. (17) They targeted the superomedial, superolateral and inferomedial genicular nerves for a conventional RF treatment because these branches are in close proximity with bony landmarks. This makes them a possible target using fluoroscopy. In this double blind randomised trial 38 elderly patient received a conventional RF treatment of 70°C for 90 seconds. They showed significant improvement in visual analogue score (VAS), Oxford knee score (OKS) and global perceived effect (GPE) at 3 months in comparison with placebo.

**NL69877.068.19****Cocogen Trial**

Since this first report, multiple publications have investigated the effect of conventional and later also, cooled RF treatment of the genicular nerves. (20-23) The use of cooled radiofrequency treatment was first described for the treatment of low back pain after which it found its introduction in the treatment of chronic knee pain in 2015. (22-26) The use of cooled electrodes increases lesion size by removing heat from adjacent tissue and allowing power delivery to be increased without tissue scarring and high impedance. (24) A prior study showed a higher success percentage and possibly a longer effect with the use of cooled radiofrequency. (23) On the other hand, the use of a cooled radiofrequency is associated with a higher product cost. In current practice, cooled RF is increasingly being used and is slowly replacing conventional RF treatment, despite evidence on its superiority. We however, hypothesize that the cheaper conventional RF treatment is not inferior to cooled RF, and may save substantial costs. A comparison between conventional and cooled radiofrequency has not been performed yet.

This protocol outlines a study using a prospective, multicentre, double blind, randomised controlled non-inferiority pilot design to yield important information for the design of a subsequent RCT to test if conventional RF treatment is not inferior to cooled RF, and also to assess the feasibility of conducting such a large RCT in two countries. In addition, we aim to estimate the initial cost-effectiveness of conventional RF treatment compared to cooled RF treatment. The current study is set up to reflect the proposed study design of the future study as close as possible, but results of this pilot study may lead to future design changes.

NL69877.068.19

Cocogen Trial

## 2. OBJECTIVES

The primary goal is to yield information to inform the design of, and evaluate the feasibility of, a future large randomised controlled non-inferiority trial to assess whether the effect of conventional RF treatment of the genicular nerves (superomedial, superolateral and inferomedial) of the index knee on knee pain relief is not inferior to the more expensive cooled RF treatment of the genicular nerves. The secondary goal is to estimate the initial cost-effectiveness of conventional RF treatment compared to cooled RF treatment so as to determine the need, focus and scope of an economic evaluation in the definitive RCT.

By first performing a pilot study we want to obtain an estimate of treatment effects and an insight into rates of inclusion. We will also be able to judge whether the international collaboration between a Belgian and 2 Dutch hospitals participating in this trial is feasible, and we'll be able to judge whether there are substantial differences in the populations of patients that both countries draw a sample from that may have an effect on the subsequent trial (e.g., the need for multilevel analysis or the need for stratified analysis).

By analysing treatment effect size we will be able to calculate a more accurate sample size for the future RCT. At the moment it is difficult to predict inclusion rates since the patient group of knee pain due to osteoartrose has variety of treatment options of which the investigated treatment is only one.

NL69877.068.19

Cocogen Trial

### 3. STUDY DESIGN

This study is designed as a prospective, multicentre, double blind, randomised controlled non-inferiority pilot trial. The total follow up time is 12 months with follow up assessments at 1, 3, 6 and 12 months post intervention. It is estimated that the total duration of data collection will cover 2 year. Patients will be randomly selected for treatment with conventional RF treatment or cooled RF treatment of the SL, SM and IL genicular nerves. In total, three hospitals participate in this study: Ziekenhuis Oost-Limburg (Belgium), Maastricht UMC+ (Netherlands) and Rijnstate (Netherlands).

An overview of the main procedures that participants undergo is provided in figure 1, Appendix A.

NL69877.068.19

Cocogen Trial

## 4. STUDY POPULATION

### 4.1 Population (base)

Adult patients with chronic, moderate to severe anterior knee pain (NRS>4) due to osteoarthritis, radiological diagnosed to be graded 2-4 according to the Kellgren-Lawrence criteria on Rx or MRI or with persistent postoperative pain after TKA. (27,28) In the patients group with persistent pain after a TKA an extensive orthopaedic workout did not reveal any other therapeutic solutions. Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in term of such damage. (29)

### 4.2 Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Age  $\geq$  18 years
- Able to understand the informed consent form and provide written informed consent and able to complete outcome measures.
- Chronic anterior knee pain (> 12 months) with an NRS > 4 on most or all days for the index knee either constantly or with motion.
- Unresponsive to conventional treatments continued during 12 months including physiotherapy, oral analgesics or intra-articular infiltrations.
- Radiologic confirmation of arthritis of OA grade of 2 (mild), 3 (moderate) or 4 (severe) noted within 6 months for the index knee according the Kellgren Lawrence criteria (27) diagnosed by an independent radiologist with experience in musculoskeletal imaging on Rx or MRI (28) or patients with total knee arthroplasty of the index knee with a negative orthopaedic workout.
- Other therapies (including surgical interventions) for pain in the index knee are allowed for the period of the study follow up as long as they are documented. This is necessary to correctly estimate the costs in the cost effectiveness analyses. Allowing patients to receive additional treatments will also improve the protocol compliance.
- Agree to provide informed consent and to comply with the requirements of this protocol for the full duration of the study

### 4.3 Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

**NL69877.068.19****Cocogen Trial**

- Patient refusal to comply to protocol procedures or schedule
- Local or systemic infection (bacteraemia)
- Evidence of inflammatory arthritis or an inflammatory systemic disease responsible for knee pain
- Intra-articular injections (steroids, hyaluronic acid, platelet enriched plasma, ...) in the index knee during the 3 months prior to procedure
- Body mass index (BMI) > 40 kg/m<sup>2</sup>
- Pregnant, nursing or planning to become pregnant before the treatment. Women of reproductive age will be tested on pregnancy prior to start of the study. Participants who get pregnant after the treatment during the follow up period will not be excluded.
- Chronic widespread pain
- Patients with psychosocial dysfunction will be referred for further psychological follow up prior to possible inclusion
- Allergies to products used during the procedure
- Uncontrolled coagulopathy defined as supratherapeutic dose of anticoagulation medication.
- Uncontrolled immune suppression
- Participating in another clinical trial/investigation within 30 days prior to signing informed consent
- Patient is currently implanted with a defibrillator, neuromodulator or other electrical devices
- Radicular pain in index leg
- Patient received previous conventional or cooled radiofrequency of the index knee

**4.4 Sample size calculation**

The primary aim of this study is to provide estimates of the effect sizes of the primary and secondary outcome measures, and to estimate the inclusion rate so that we have sufficient input to determine feasibility of a future RCT and to yield input for the sample size calculation. Further design aspects, such as the need for multilevel analysis based on clusters of patients within hospitals will be assessed as well. A rule-of-thumb suggests including 12 patients per group in case of a pilot study, so that preliminary data on effect sizes and feasibility can be obtained. (30) For our study, this means 12 patients in the conventional RF group and 12 in the cooled RF group, but separately for patients with osteoarthritis and for patients with knee pain after total knee arthroplasty. Hence, we will include a total of 48 patients.

NL69877.068.19

Cocogen Trial

## 5. TREATMENT OF SUBJECTS

### 5.1 Investigational treatment

#### Procedure description

According to the recent ASRA and ESA guidelines on peripheral blockade in the anticoagulated patient, management should be based on site compressibility, vascularity, and consequences of bleeding, should it occur. (31) In the genicular radiofrequency treatment performed in this study, we judged this factors to be in favour of not stopping anticoagulation.

During the procedure the patient is monitored using pulse oximetry. No sedation is administered so the patient is able to communicate and report the stimulation adequate. The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15° by placing a cushion in the popliteal fossa. The procedure is performed under sterile conditions. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip or with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief). No diagnostic block is performed since a recent study showed no prognostic value. (32) No corticosteroids are injected to decrease the risk of complications such as systemic effects and infection. (33) Using a high frequency linear ultrasound the superomedial, the superolateral and the inferomedial genicular nerve are targeted described as below. The inferolateral genicular nerve is not targeted because of its proximity to the common peroneal nerve with its motor branches.

#### Superomedial genicular nerve

The transducer is placed in a coronal orientation on the medial side of the proximal knee. After identifying the femoral medial epicondyle, the transducer is displaced proximally and centered to the junction between the epiphysis and diaphysis of the femur and the vastus medialis superficial to it, just anterior to the adductor tubercle. The superomedial genicular artery may or may not be seen between the deep fascia of the muscle and the femur at this level. If the superomedial genicular artery is visualised just above the bony cortex, the target point is next to this artery. If the artery is not visualised, the junction between the epiphysis and diaphysis is the target point. The probe-to-target point distance is assessed with ultrasound. An out-of-plane entry point is marked perpendicular to the center of the probe at the assessed probe-to-target point distance. Consecutively, the transducer was turned 90° into the transverse plane at this point. The skin and soft tissue are anesthetized with 1 ml lidocaine 2% at the estimated entry point. The cannula is advanced using an anterior to posterior 'in plane' approach in the transverse plane until contact is made with the bony

NL69877.068.19

Cocogen Trial

cortex at the center of the femur. A RF electrode is introduced in the cannula. Sensory stimulation (50 Hz) is applied and produced paresthesia at a threshold of less than 0,5 V. The absence of fasciculations below 1 V is observed after motor stimulation at 2 Hz, confirming sufficient distance to relevant motor branches. If no sensory stimulation threshold is obtained at this position, the transducer is repositioned until sensory threshold is reached.

#### Inferomedial genicular nerve

The transducer is placed in a coronal orientation on the medial side of the distal knee to visualize the junction of the tibial medial epiphysis and diaphysis, the inferomedial genicular artery and the medial collateral ligament. If the inferomedial genicular artery is visualised just above the bony cortex beneath the medial collateral ligament at the midpoint between the tibial medial epicondyle and the tibial insertion of the medial collateral ligament, the target point is next to this artery. If the artery is not visualised, the junction between the epiphysis and diaphysis is the target point. The probe-to-target point distance is assessed with ultrasound. An out-of-plane entry point is marked perpendicular to the center of the probe at the assessed probe-to-target point distance. Consecutively, the transducer was turned 90° into the transverse plane at this point. The skin and soft tissue are anesthetized with 1 ml lidocaine 2% at the estimated entry point. The cannula is advanced using an anterior to posterior 'in plane' approach in the transverse plane until contact is made with the bony cortex at the center of the tibia. A RF electrode is introduced in the cannula. Sensory stimulation (50 Hz) is applied and produced paresthesia at a threshold of less than 0,5 V. The absence of fasciculations below 1 V is observed after motor stimulation at 2 Hz, confirming sufficient distance to relevant motor branches. If no sensory stimulation threshold is obtained at this position, the transducer is repositioned until sensory threshold is reached.


#### Superolateral genicular nerve

The transducer is placed in a coronal orientation on the lateral side of the proximal knee. After identifying the femoral lateral epicondyle, the transducer is displaced proximally to image the junction between the epiphysis and diaphysis of the femur and the vastus lateralis superficial to it. The superolateral genicular artery may or may not be seen between the deep fascia of the muscle and the femur at this level. If the superolateral genicular artery is visualised just above the bony cortex, the target point is next to this artery. If the artery is not visualised, the junction between the epiphysis and diaphysis is the target point. The probe-to-target point distance is assessed with ultrasound. An out-of-plane entry point is marked perpendicular to the center of the probe at the assessed probe-to-target point distance. Consecutively, the transducer was turned 90° into the transverse plane at this point. The skin and soft tissue are anesthetized with 1 ml lidocaine 2% at the estimated entry point. The

NL69877.068.19

Cocogen Trial

cannula is advanced using an anterior to posterior 'in plane' approach in the transverse plane until contact is made with the bony cortex at the center of the femur. A RF electrode is introduced in the cannula. Sensory stimulation (50 Hz) is applied and produced paresthesia at a threshold of less than 0,5 V. The absence of fasciculations below 1 V is observed after motor stimulation at 2 Hz, confirming sufficient distance to relevant motor branches. If no sensory stimulation threshold is obtained at this position, If no sensory stimulation threshold is obtained at this position, the transducer is repositioned until sensory threshold is reached.



*Fig. Ultrasound probe position and corresponding images for genicular radiofrequency treatment. Color Doppler shows the corresponding genicular arteries. Treatment sites are marked with yellow asterisks.*

If all three target nerves were identified, a control fluoroscopy image is made to confirm the needle tip position. First, an AP view is made and the needle tip should be at the junction between the diaphysis and the epiphysis touching the bony cortex. Second, a lateral view is made where the needle tip should be within the 2 middle quarters of the femur width.

If the needle tip is confirmed to be in the correct position 1 ml of lidocaine 2% is injected before the start of a RF treatment. In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve. In the cooled radiofrequency

18

**NL69877.068.19****Cocogen Trial**

---

group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.

After the procedure, the patient is transferred to the recovery. After 30 minutes without any events, the patient is discharged at home. Home medication is continued postoperative. Patient is informed about potential transient increase in pain due to neuritis and alarm symptoms (fever, swelling, bleeding and motor weakness).

### **5.2 Use of co-intervention**

It is allowed to use other medication or undergo an intervention as long as documented to be able to adequate estimate costs.

### **5.3 Escape medication**

The use of all medication is allowed as long as documented. This enables the researchers to adequate estimate costs.

NL69877.068.19

Cocogen Trial

## 6. NON-INVESTIGATIONAL PRODUCT

The medical products used in this study are used as in usual clinical practice. The 'CE certificates' and 'instructions for use' of each medical product are to be found in Appendix B and C.

### 6.1 Name and description of non-investigational product(s)

The following is a summary description of the used study device. For additional information, please refer to the COOLIEF "Instructions for Use" (Appendix B). The COOLIEF™ system is composed of three primary components (collectively known as 'disposables') and is used in conjunction with the pain management generator, pump unit, connector cables (collectively known as 'Hardware') and dispersive electrodes (also known as 'grounding pads'):

- Cooled radiofrequency sterile tube kit (sterile, single use, non-body contact): it is used for closed-loop circulation of sterile water through a Halyard cooled radiofrequency probe. It includes a burette and tubing.
- Cooled radiofrequency introducer (sterile, single use, 100 mm, 17 gauge, straight): it is to be used with the probes only. The cooled radiofrequency introducer provides a path for the probe to the targeted nervous tissue.
- Cooled radiofrequency probe (sterile, single use, 18 gauge): it is inserted through an introducer into or near nervous tissue. The active tip extends 4 mm from the introducer and delivers energy. Sterile water circulates internally to cool the probe while it delivers radiofrequency energy. A thermocouple in the probe measures the cooled electrode temperature throughout the procedure.

The product is comprised of an electrically insulated shaft with an active tip that functions as an electrode for RF energy delivery, a handle, tubes with luer locks and a cable with a 7-pin connector. The introducer includes an insulated stainless steel cannula and a stylet. The tube kit is comprised of a burette and flexible tubing fitted with luer locks for connection to the probe.

The following is a summary description of the used control device. For additional information, please refer to the "Instructions for Use" (Appendix C). The control device to produce a conventional radiofrequency lesion is composed of two primary components and is used in conjunction with the same pain management generator, connector cables and dispersive electrodes (also known as grounding pads) (Halyard) as in the study group.

**NL69877.068.19****Cocogen Trial**

- Radiofrequency introducer (sterile, single use, 100 mm, 18 gauge, straight): it is to be used with the probes only. The radiofrequency introducer provides a path for the probe to the targeted nervous tissue.
- Radiofrequency probe (sterile, single use): it is inserted through an introducer into or near nervous tissue. The active tip extends 10 mm from the introducer and delivers energy. A thermocouple in the probe measures the electrode temperature throughout the procedure.

**6.2 Summary of findings from clinical studies**

The treatment performed with the COOLIEF™ system is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures to deactivate nerves that are responsible for transmitting pain signals. (24). The system uses water-cooled technology to deactivate pain transmission. (24)

**6.3 Preparation and labelling of Non Investigational Medicinal Product**

The probe, introducer, and tube kit are ethylene oxide sterilized and supplied sterile. These components can be packaged together in a kit or as separate components. The devices should be stored in a cool, dry environment. The 'Instructions For Use' (IFU) documents (Appendix B and C) are included in each kit.

NL69877.068.19

Cocogen Trial

## 7. METHODS

### 7.1 Study parameters/endpoints

Endpoints are chosen following the IMMPACT guidelines which recommend 6 core outcome domains in chronic pain research. (34) These domains are:

1. Pain
2. Physical functioning
3. Emotional functioning
4. Participant ratings of improvement and satisfaction with treatment
5. Symptoms and adverse events
6. Participant disposition

Furthermore, inclusion rate will also be monitored.

#### 7.1.1 Main study parameter/endpoint

The primary study parameter is the proportion of patients with a pain reduction of at least 50% at three months post intervention. Pain intensity is expressed as a number from the numerical rating scale. Absolute NRS scores are also collected at each visit. A pain diary of multiple NRS during 4 days will be collected to achieve a more complete and trustworthy idea of pain.

In this study we will use a threshold of 50% although IMMPACT guidelines only recommend a threshold of 30% because in the clinical setting the 50% threshold is most often used, as well in previous studies. This makes comparison within the literature easier.

NRS is a unidimensional, subjective measurement of pain intensity, expressed by the patient as a number between 0 and 10. It is a 11 point scale in which 0 equals no pain and 10 maximal pain. (35)

Furthermore, at one, three, six and twelve months post intervention the patients are also asked whether the pain is acceptable.

A month is defined as 30 days with 4 days before or after this timepoint.

At 12 months a time window of 2 weeks before and there the timepoint is accepted.

#### 7.1.2 Secondary study parameters/endpoints

The secondary parameters are:

- Patient self-reported impression of change, measured by the Patient's Global Impression of Change (PGIC) at 1, 3, 6 and 12 months. The impression of change is measured using a 7 point likert scale. (36)

## NL69877.068.19

## Cocogen Trial

- The change in medication use, measured by the change in Medication Quantification Scale III (MQS III). The MQS is designed as a methodology of quantifying different drug regimens in 1992 and updated in 1998 (MQS II) and 2003 (MQS III) using detriment weights determined by surveying physician members of the American Pain Society. (37) This will be recorded at baseline, 1, 3, 6 and 12 months post intervention.
- The duration of pain relief. This is defined as the time interval in which a NRS reduction of more than 50% is obtained or in which the pain is still acceptable without the usage of other additional therapies (increase in MQS 3 score of more than 50%, intra-articular infiltration, operation)
- The change in physical function from baseline to 3, 6 and 12 months post intervention. This will be measured by the change in the Oxford Knee Score (OKS). (38) The OKS is a patient-reported measure assessing pain intensity and physical function. The list consists of 12 items scored from 1 to 5, with 0 representing normal function/ least symptoms. Objectively, knee function will be measured through goniometry by using the CJOrtho app and by 'timed up and go' test. (39, 40) The measurement of maximal knee flexion and extension is performed in a standardised manner and photos of each position will be kept for review. The 'Timed Up and Go' test assesses patients' functional mobility of the lower extremities. Participants are timed with a stopwatch while standing up from a chair, walking 3 meters (in a comfortable and safe way), come back and sit back in the chair. The objective parameters of physical function will not be obtained at 12 months.
- The change in health-related quality of life, measured by the change in EQ-5D-5L, between baseline and 6 and 12 months post intervention. (41) The EQ-5D-5L is a patient-reported generic measure of HRQoL comprising five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses to the 5 items (one for each dimension) result in a patient's health state that can be transformed into a utility score ranging between 0 (death) and 1 (full health), representing the quality of life of the health state. (41). The EQ-5D-5L is assessed at baseline and at 1, 3, 6 and 12 months post intervention.
- Change in characteristic attitudes and symptoms of depression from baseline to 3, 6 and 12 months post intervention. This will be measured by the change in Hospital Anxiety and Depression Scale (HADS) and in Pain Catastrophizing Scale (PCS) from baseline to 6 and 12 months. (42, 43) HADS is developed to detect anxiety and depression in patients with physical health problems. The questionnaire consists of 14 items: 7 items to measure anxiety and 7 items to measure depression. The PCS is often used in clinical settings to measure catastrophic thinking related to pain. The 13 item questionnaire consists of 3 subscales (magnification, rumination and helplessness) and asks patients to

**NL69877.068.19****Cocogen Trial**

reflect on past painful experiences and to indicate the degree on which they experiences each of 13 thoughts of feelings on a 5- point scale (0 not at all and 4 all the time).

- Amount of Adverse Events and/or Serious Adverse Events. Active capture during each site visit to assess specific symptoms and adverse events that are relevant to chronic knee pain or RF treatment.
- Costs in both intervention groups. Costs include health care related costs (e.g. intervention cost, medication), costs to patients and family (e.g. travel costs, out-of-pocket payments), and costs due to lost productivity. Complete individual level hospital resource use data (e.g. surgical intervention, diagnostic procedures, hospital admissions, outpatient clinic visits) will be measured using medical records and by means of a self-developed questionnaire to be completed by patients, based on the iMTA Medical Consumption Questionnaire as recommended in the Dutch guideline for economic evaluation. (44) The questionnaire will have a recall period of 3 months and will be administered repeatedly at baseline, 3, 6 and 12 months post intervention. The Dutch manual for costing research will be used to determine prices for each volume of resource use. (45)
- Cost-effectiveness will be expressed using incremental cost-effectiveness ratios (e.g. incremental cost per QALY, incremental cost per reduced point on the pain score, and incremental costs per additional treatment success). QALYs (Quality Adjusted Life Years) will be calculated by multiplying life years with the health-related quality of life during these life years as measured by the EQ-5D-5L.
- At 12 months in the osteoarthritis group, we ask if a total knee arthroplasty is performed and if so at which timepoint.
- All used questionnaires to retrieve the above mentioned outcome parameters can be found in Appendix D.

### **7.1.3 Other study parameters**

Inclusion rates will also be monitored.

### **7.2 Randomisation, blinding and treatment allocation**

Final inclusion of a patient follows after written informed consent. Included patients will be subscribed by the central trial coordinator and the data management centre. The data management centre is responsible for the randomisation procedure, which will be performed with the software program CASTOR. Randomisation is justified because both treatments are similar with similar risks since the cooled radiofrequency is a modification of the conventional technique. The cooled radiofrequency however has the potential benefit of higher chance of therapy success (pain reduction) and longer duration of therapy success. Every patient from

NL69877.068.19

Cocogen Trial

or the total knee arthroplasty group, or the osteoarthritis group, will be divided into one of the treatment groups at random so that half of every patient population (TKA and OA) received cooled and half conventional radiofrequency treatment. The randomisation ratio is 1:1. Patients in group 1 will receive conventional RF treatment, and patients in group 2 are being treated with cooled RF treatment.

The patients are treated by a pain physician who is not involved in the follow-up treatment. The blinding of each patient enrolled in this study is tested approximately 30 minutes after the treatment by asking the patient what they think they have received. At the 6 months follow-up, the patient is deblinded.

### 7.3 Study procedures

Patients will be in follow up for 6 months. There are 4 site visits. T0 to collect baseline parameters after which the intervention is performed. T1 at one month post intervention. T2 at 3 months post intervention at which the primary endpoint is collected. T3 at 6 months post intervention.

Table 1 (Appendix E) provides an overview of all study procedures per follow up moment. There is a distinction between study procedures at site and study procedures at home.

### 7.4 Withdrawal of individual subjects

Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons.

### 7.5 Premature termination of the study

Premature termination is only possible:

- if the judgement of the competent medical research ethics committee that has assessed the study is irrevocably revoked;
- if a reasonable case can be made for terminating the study in the interests of the health of the research subjects;
- if it transpires that continuation of the study cannot serve any scientific purpose, and this is confirmed by the medical research ethics committee that has issued a positive decision on the study;
- if one of the parties or the funder has been declared insolvent or a bankruptcy/winding-up petition has been filed in respect of one of the parties or the financier, or one of the parties or the financier is dissolved as a legal entity;

**NL69877.068.19****Cocogen Trial**

---

- if the principal investigator is no longer capable of performing the tasks of the principal investigator, and no replacement agreeable to both parties can be found;
- if one of the two parties fails to comply with the obligations arising from the agreement and, provided compliance is not permanently impossible, this compliance has not taken place within thirty days of the defaulting party receiving a written request to comply, unless failure to comply is not in reasonable proportion to the premature termination of the study;
- if circumstances beyond the control of the sponsor, investigator or funder make it unreasonable to require the study's continuation.

NL69877.068.19

Cocogen Trial

## 8. SAFETY REPORTING

### 8.1 Temporary halt for reasons of subject safety

In accordance to section 10, subsection 4, of the WMO, the sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardise subject health or safety. The sponsor will notify the accredited METC without undue delay of a temporary halt including the reason for such an action. The study will be suspended pending a further positive decision by the accredited METC. The investigator will take care that all subjects are kept informed.

### 8.2 AEs, SAEs and SUSARs

#### 8.2.1 Adverse events (AEs)

Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational intervention. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded.

The potential risks to subjects in which a radiofrequency neurotomy procedure is performed, regardless of the treatment modality, may include the following, all of which are anticipated adverse events that have been identified as possible complications of procedures involving lesioning of nervous tissue:

- Infection,
- Damage to collateral nervous tissue,
- Increased pain,
- Failure of technique,
- Superficial burns,
- Damage to collateral tissue (i.e., bruising or hematoma),
- Deafferentation dysesthesia
- Paralysis
- Allergy

Subjects should be instructed to contact the investigator immediately if an AE occurs. At each visit, the investigator should further query the subject to determine if any new adverse events have occurred. Adverse events will be assessed and reported from the time the subject signs consent until study exit according to the following procedure.

NL69877.068.19

Cocogen Trial

The investigator will assess the severity of each AE based on the following definitions:

Severity	Definition
Mild	An AE in which the subject is aware of signs or symptoms, but which does not interfere with the subject's usual activities of daily living, or is transient and resolves without treatment or sequelae.
Moderate	A sign or symptom which interferes with the subject's usual activities of daily living or requires treatment.
Severe	Any event listed as serious adverse event.

For each AE, the investigator will assess the causality/relationship to the received treatment according to the following criteria:

Relatedness	Definition
Possible	The association of the AE with the test article is unknown; other etiologies are also possible.
Probable	A reasonable temporal sequence of the AE with test article administration exists and based upon the medical professional's clinical experience, the association of the AE with the test article seems likely.
Definite	A causal relationship exists between the received treatment and the AE, and other conditions (e.g., concomitant illness, progression or expression of the disease state, reaction to concomitant medications) do not appear to explain the AE.

All AEs must be recorded in the subject's medical record and the appropriate eCRF. The description of the AE will identify the date of onset, date of remission, severity, causal relationship to the study treatment, action taken along with the results of any diagnostic procedures or laboratory tests, all treatments that were required and the outcome of the AE.

### 8.2.2 Serious adverse events (SAEs)

A serious adverse event is any untoward medical occurrence or effect that

- results in death;
- is life threatening (at the time of the event);
- requires hospitalisation or prolongation of existing inpatients' hospitalisation;
- results in persistent or significant disability or incapacity;
- any other important medical event that did not result in any of the outcomes listed above due to medical or surgical intervention but could have been based upon appropriate judgement by the investigator.

NL69877.068.19

Cocogen Trial

- An elective hospital admission will not be considered as a serious adverse event.

Sites will be instructed to follow their normal routine processes for adverse event reporting. However, serious adverse events will be specifically monitored for. The sponsor will report the possible, probable or definite related SAEs through the web portal 'ToetsingOnline' to the accredited METC that approved the protocol, within 7 days of first knowledge for SAE's that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the sponsor has first knowledge of the serious adverse events. All reported SAE's will be mentioned to the accredited METC that approved the protocol in a yearly summary.

### **8.2.3 Suspected unexpected serious adverse reactions (SUSARs)**

These will be dealt with as any serious adverse reaction as described as above.

### **8.3 Annual safety report**

N.A.

### **8.4 Follow-up of adverse events**

All AEs will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist. SAEs need to be reported till end of study within the Netherlands, as defined in the protocol.

### **8.5 Data and Safety monitoring board**

Given the nature of this study a Data and Safety Monitoring Board (DSMB) is not required based on the FDA guidance document, "Establishment and Operation of Clinical Trial Data Monitoring Committees" and EMA guideline "Guideline on data monitoring committees". Monitoring of the data is requested and would be performed by a clinical research monitor (CTCM).

NL69877.068.19

Cocogen Trial

## 9. STATISTICAL ANALYSIS

Patient baseline characteristics will be described for both knee pain groups separately, and stratified by treatment allocation using mean and standard deviation or median and interquartile range for continuous variables, and count and percentage for categorical variables. Incomplete patients records will be imputed using multiple imputation to allow analysis on all randomised subjects.

All outcome measures will be computed on the intention to treat sample.

### 9.1 Primary study parameter(s)

The primary outcome, the proportion of patients reporting treatment success at 3 months after treatment, will be described per group as count with percentage and 95% confidence interval. In addition, we will report the mean change from baseline on the NRS, including standard deviation and 95% confidence interval. Furthermore, we will compute the difference in proportion of success between groups and the difference in mean change from baseline between groups, both with 95% confidence interval. The lower bound of the 95% confidence interval of the difference will be compared to the non-inferiority limit. However, the latter part will be used only for exploratory purposes, due to the nature of the study design (i.e. pilot study).

### 9.2 Secondary study parameter(s)

All hypothesis testing will be explorative in nature, and thus secondary to describing the outcome measures. The confidence interval of the difference between groups will be used to test non-inferiority of conventional RF compared to cooled RF. In case the point estimate of the difference in proportion of treatment effect between groups will be below the non-inferiority limit, this will be suggestive of non-inferiority. In that case, we will use the results of this study to calculate the necessary sample size for a future randomized controlled non-inferiority trial.

Other secondary study parameters (MQS III, PGIC, duration of pain relief, OKS, the Timed Up and Go test, goniometry, HADS, PCS, EQ-5D-5L, performance of a TKA and the amount of Adverse Events and/or Serious Adverse Events) will be reported as mean or percentage difference including 95% confidence interval. Hypothesis testing will be performed using the independent t-test for continuous variables, and Fisher's Exact test for categorical variables. This will only be regarded as explorative in nature.

**NL69877.068.19****Cocogen Trial**

---

**COST EFFECTIVENESS ANALYSIS (CEA)**

Economic evaluation comparing conventional to cooled RF treatment will be performed with a time horizon of 6 months. Cost-effectiveness will be assessed by evaluating the incremental cost-effectiveness ratios using several perspectives: societal cost per QALY (based on EQ-5D-5L), healthcare cost per reduced point on the pain score, and healthcare costs per additional treatment success. Standard bootstrap and sensitivity analysis will be performed to address uncertainty surrounding the findings.

**9.3 Other study parameters**

Descriptive statistics will be used to report inclusion rates in function of feasibility of a future RCT.

NL69877.068.19

Cocogen Trial

## 10. ETHICAL CONSIDERATIONS

### 10.1 Regulation statement

The study will be conducted according to the principles of the Declaration of Helsinki (version 8, October 2013) and in accordance with the Medical Research Involving Human Subjects Act (WMO).

### 10.2 Recruitment and consent

Potential eligible patients for this study are informed about the study by their pain physicians. If the patient shows interest in potential participation, the pain physician provides the patient with the patient information letter and asks permission for a researcher to contact the patient. During this conversation the researcher provides additional information and answers any questions the patient may have. The researcher asks the patient consent to contact the patient minimal 7 days later to ask whether the patient has any questions/ concerns and if the patient has made a decision whether or not to participate in the study. The patient can contact the researcher on his own discretion after the informative conversation if he decides to participate. If the patient decides to participate in the study, the patient is scheduled for treatment. Prior to the treatment both patient and researcher sign the informed consent document followed by baseline measurement.

### 10.3 Objection by minors or incapacitated subjects (if applicable)

Not applicable. Minors or incapacitated adults are excluded in this study.

### 10.4 Benefits and risks assessment, group relatedness

Patients in both treatment groups have the opportunity to benefit from positive treatment effects (pain relief, functional improvement, improved quality of life). The additional risks associated with either treatment options can be expected to be very low. Potential side effects of the treatment are haematoma, infection, temporary increase of pain, hypesthesia, paresthesia and neuralgia or paralysis, superficial burns, damage to collateral nervous tissue of soft tissue, failure of technique and allergy. (17, 23, 41)

Since the prevalence of osteoarthritis is rising, the burden of this disease and the risks and cost associated with total knee replacement are also rising. (46)(47) Therefore, there is a need for minimal invasive technique to treat osteoarthritis. In the recent literature there are different reports, primarily in the USA, about the effectiveness of cooled radiofrequency. In Europe there is at the moment no indication for this treatment due to the lack of reimbursement. Therefore there is a need for a randomised control trial with a head to head

NL69877.068.19

Cocogen Trial

comparison to evaluate if the newer modification of a radiofrequency treatment is as effective and also cost effective in comparison with the conventional radiofrequency treatment in Belgium and The Netherlands. This study has a scientific merit with minimal risk for the participants.

### **10.5 Compensation for injury**

The sponsor/investigator has a liability insurance which is in accordance with article 7 of the WMO. So the sponsor has an insurance at each site which is in accordance with the legal requirements in the Netherlands (Article 7 WMO) and in Belgium (Article 29, Law 7 may 2004). This insurance provides cover for damage to research subjects through injury or death caused by the study.

The insurance applies to the damage that becomes apparent during the study or within 4 years after the end of the study.

(Proefpersonenverzekering, verzekeringsverklaring Model 1).

(Sponsor liability insurance MUMC+, CNA Insurance); Rijnstate, Medirisk)

### **10.6 Incentives**

The study participants will not receive financial compensation for their study participation. Parking costs will be reimbursed with a maximum of 12,5 euro per visit. There will be no difference in costs in comparison with regular care due to participation in this study since both treatment groups are standard of care.

NL69877.068.19

Cocogen Trial

## 11. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION

### 11.1 Handling and storage of data and documents

All data collected during this study will be handled confidentially. The data of each study participant will be coded (001, 002, 003 etc, 001M for MUMC+, 001R for Rijnstate, 001Z for ZOL). By use of a study number to secure data security and the privacy of study participants according to the EU General Data Protection Regulation and the Dutch Act on Implementation of the General Data Protection Regulation. A subject identification code list is safeguarded by the principal investigators. The principal investigator, monitors and researchers have access to the source data. The data will be kept for 20 years after completion of the study by the data management centre.

Data obtained from this study can be used in the future larger study on the treatment of chronic knee pain and only coded data of participants who gave informed consent will be used. This data, obtained from the current study, will be stored and can be used in other research about the treatment of chronic knee pain. Informed consent to use this data will be obtained.

### 11.2 Amendments

Amendments are changes made to the research after a favourable opinion by the accredited METC has been given. All amendments will be notified to the METC that gave a favourable opinion.

### 11.3 Annual progress report

The sponsor/investigator will submit a summary of the progress of the trial to the accredited METC once a year. Information will be provided on the date of inclusion of the first subject, numbers of subjects included and numbers of subjects that have completed the trial, serious adverse events/ serious adverse reactions, other problems, and amendments.

### 11.4 Temporary halt and (prematurely) end of study report

The sponsor will notify the accredited METC and the competent authority of the end of the study within a period of 8 weeks. The end of the study is defined as the last patients last visit.

The sponsor will notify the METC immediately of a temporary halt of the study, including the reason of such an action.

In case the study is ended prematurely, the sponsor will notify the accredited METC and the competent authority within 15 days, including the reasons for the premature termination.

---

**NL69877.068.19****Cocogen Trial**

Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the accredited METC and the Competent Authority.

#### **11.5 Public disclosure and publication policy**

All study results will be published without restrictions. This means that patients grant the sponsor the right to publish the study results, based on their participation in the study. All members of the study groups agree that all study results will be published. No veto right exists. Both negative and positive results will be published. Before publication, all authors will have the opportunity to give comments on the manuscript. Data will be published as soon as possible after finishing data analysis.

## 12. REFERENCES

1. Allen KD, Golightly YM. State of the evidence. *Current Opinion in Rheumatology*. 2015;27(3):273-275.
2. Garstang SV, Stitik TP. Osteoarthritis: Epidemiology, risk factors, and pathophysiology. *American Journal of Physical Medicine & Rehabilitation*. 2006;85(11):S2-S11.
3. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. *The Lancet*. 2011;377(9783):2115-2126.
4. Hopman-Rock M, Odding E, Hofman A, Kraaijmaat FW, Bijlsma JWJ. Physical and psychosocial disability in elderly subjects in relation to pain in the hip and/or knee. *The Journal of Rheumatology*. 1996;23(6):1037-44.
5. Trasolini NA, McKnight BM, Dorr LD. The opioid crisis and the orthopedic surgeon. *The Journal of Arthroplasty*. 2018;33(11):3379-82.
6. Dhawan A, Mather RC, Karas VK, Ellman MB, Young BB, Bach BR, et al. An epidemiologic analysis of clinical practice guidelines for non-arthroplasty treatment of osteoarthritis of the knee. *Arthroscopy: the Journal of Arthroscopic and Related Surgery*. 2014;30(1):65-71.
7. Langworthy MJ, Saad A, Langworthy NM. Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment. *The Physician and Sportsmedicine*. 2010;38(2):133-45.
8. Guidelines Acorsoo. Recommendations for the medical management of osteoarthritis of the hip and knee. *Arthritis & Rheumatism*. 2000;43(9):1905-15.
9. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. *Osteoarthritis Cartilage*. 2016;24(6):962-72.
10. Lui SS, Buvanendran A, Rathmell JP, Sawhney M, Bae JJ, Moric M, et al. A cross sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. *Regional Anesthesia and Pain Medicine*. 2012;37(4):415-22.
11. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. *PAIN*. 2011;152(3):566-72.
12. Scranton PE. Management of knee pain and stiffness after total knee arthroplasty. *The Journal of Arthroplasty*. 2001;16(4):428-35.
13. Albayrak I, Apiliogullari S, Erkocak OF, Kavalci H, Ozerbil OM, Levendoglu F. Total knee arthroplasty due to knee osteoarthritis: risk factors for persistent postsurgical pain. *Journal of the National Medical Association*. 2016;108(4):236-43.
14. Drosos GI, Triantafyllidou T, Ververidis A, Aggelopoulou C, Vogiatzaki T, Kazakos K. Persistent post-surgical pain and neuropathic pain after total knee replacement. *World Journal of Orthopedics*. 2015;6(7):528-36.

NL69877.068.19

Cocogen Trial

15. Thomazeau J, Rouquette A, Martinez V, Rabuel C, Prince N, Laplanche JL, et al. Predictive factors of chronic post-surgical pain at 6 months following knee replacement: influence of postoperative pain trajectory and genetics. *Pain Physician*. 2016;19(5):E729-E41.
16. Lewis GN, Rice DA, McNair PJ, Kluger M. Predictors of persistent pain after total knee arthroplasty: a systematic review and meta-analysis. *Survey of Anesthesiology*. 2015;59(5):247-8.
17. Choi WJ, Hwang SJ, Song JG, Leem JG, Kang YU, Park PH, et al. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *PAIN*. 2011;152(3):481-7.
18. Franco CD, Buvanendran A, Petersohn JD, Menzies RD, Menzies LP. Innervation of the anterior capsule of the human knee: implications for radiofrequency ablation. *Regional Anesthesia and Pain Medicine*. 2015;40(4):363-8.
19. Horner G, Dellon AL. Innervation of the human knee joint and implications for surgery. *Clinical Orthopaedics and Related Research*. 1994;301:221-6.
20. Bhatia A, Peng P, Cohen SP. Radiofrequency procedures to relieve chronic knee pain: an evidence-based narrative review. *Regional Anesthesia and Pain Medicine*. 2016;41(4):501-10.
21. Qudsi-Sinclair S, Borrás-Rubio E, Abellan-Guillén JF, Padilla del Rey ML, Ruiz-Merino G. A comparison of genicular nerve treatment using either radiofrequency or analgesic block with corticosteroid for pain after total knee arthroplasty: a double blind, randomized clinical study. *Pain Practice*. 2017;17(5):578-88.
22. Gupta A, Huettnner DP, Dukewich M. Comparative effectiveness review of cooled versus pulsed radiofrequency ablation for the treatment of knee osteoarthritis: a systematic review. *Pain Physician*. 2017;20(3):155-71.
23. Davis T, Loudermilk E, DePalma M, Hunter C, Lindley C, Patel N, et al. Prospective, multicenter, randomized, crossover clinical trial comparing the safety and effectiveness of cooled radiofrequency ablation with corticosteroid injection in the management of knee pain from osteoarthritis. *Regional Anesthesia and Pain Medicine*. 2018;43(1):84-91.
24. Kapural L, Nageeb F, Kapural M, Cata JP, Narouze S, Mekhail N. Cooled radiofrequency system for the treatment of chronic pain from sacroiliitis: the first case-series. *Pain Practice*. 2008;8(5):348-54.
25. Stelzer W, Aiglesberger M, Stelzer D, Stelzer V. Use of Cooled Radiofrequency Lateral Branch Neurotomy for the Treatment of Sacroiliac Joint-Mediated Low Back Pain: A Large Case Series. *Pain Medicine*. 2013;14(1):29-35.

NL69877.068.19

Cocogen Trial

26. Ho KY, Hadi MA, Pasutharnchat K, Tan KH. Cooled radiofrequency denervation for treatment of sacroiliac joint pain: two-year results from 20 cases. *Journal of pain research*. 2013;6:505-11.
27. Kellgren JH, Lawrence JS. Radiological assessment of osteo- arthrosis. *Annals of the Rheumatic Diseases*. 1957;16(4):494-502.
28. Park H, Kim S, Lee S, Park N, Park J, Choi Y, Jeon H. A practical MRI grading system for osteoarthritis of the knee: Association with Kellgren–Lawrence radiographic scores. *European journal of radiology*. 2013; 82: 112-117.
29. Part III: Pain Terms, A Current List with Definitions and Notes on Usage. p 209-214. *Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy*, edited by H. Merskey and N. Bogduk, IASP Press, Seattle, ©1994
30. Steven A. Julious. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceut. Statist*. 2005; 4: 287-291.
31. Horlocker T, Vandermeulen E, Kopp S, Gogarten W, Leffet L, Benzon H. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) *Regional Anesthesia and Pain Medicine*; 2018(4);43(3):263-309.
32. McCormick ZL, Reddy R, Korn M, et al. A prospective randomised trial of prognostic genicular nerve blocks to determine the predictive value for the outcome of cooled radiofrequency ablation for chronic knee pain due to osteoarthritis. *Pain Medicine* 2018 Aug 1;19(8):1628-38.
33. Khanna A, Knox N, Sekhri N. Septic arthritis following radiofrequency ablation of the genicular nerves. *Pain Medicine*. 2019;0(0):1-3.
34. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2005;113(1):9-19.
35. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. *Pain*. 1993;55(2):195-203.
36. Farrar JT, Young JP, Lamoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain*. 2002;94(2):149.
37. Steedman SM, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC. Chronic-Pain Medications: Equivalence Levels and Method of Quantifying Usage. *The Clinical Journal of Pain*. 1992;8(3):204-14.
38. Haverkamp D, Breugem SJM, Siervelt IN, Blankevoort L, Van Dijk CN. Translation and validation of the Dutch version of the Oxford 12-item knee questionnaire for knee arthroplasty. *Acta Orthop*. 2005; 76: 347-52.

NL69877.068.19

Cocogen Trial

39. Reina N, Cognault J, Olivier M, Dagneaux L, Gauci MO, Pailé R. The CJOrtho app: a mobile clinical and educational tool for orthopedics. *Orthop Traumatol Surg Res*. 2018 Jun;104(4):523-27.
40. Podsiadlo D, Richardson S. The timed 'Up & Go': a test of basic functional mobility for frail elderly persons. *Journal of the American Geriatrics Society*. 1991;39(2):142-8.
41. Versteegh M, Vermeulen M, Evers M, et al. Dutch tariff for the Five-level version of EQ-5D. *Value Health* 2016 jun; 19(4): 343-52.
42. Snaith RP, Zigmond AS. The hospital anxiety and depression scale. *British Medical Journal*. 1986;292(6516):344.
43. Sullivan MJL. The Pain Catastrophizing Scale: Development and Validation. *Psychological Assessment*. 1995;7(4):524-32.
44. Bouwmans C, Hakkaart-van Rooijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. Guideline iMTA Medical Consumption Questionnaire. 2013.
45. Zorginstituut Nederland (2016 ) Kostenhandleiding—methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg (Guideline for costing research in economic evaluations in health care). Zorginstituut Nederland, Diemen.
46. Ackerman IN, Bohensky MA, Zomer E, Tacey M, Gorelik A, Brand CA, et al. The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. *BMC Musculoskelet Disord*. 2019;20(1):1–10.
47. Vos T, Allen C, Arora M, Barber RM, Brown A, Carter A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1545–602.

NL69877.068.19

Cocogen Trial

**13. APPENDIX.****Appendix A**

Participant flow diagram

**Appendix B**

'Instruction for use' of Coolief radiofrequency (Halyard)

'CE' of Coolief radiofrequency (Halyard)

**Appendix C**

'Instruction for use' of conventional radiofrequency (Halyard)

'CE' of conventional radiofrequency (Halyard)

'Instruction for use' of generator (Halyard)

'CE' of generator (Halyard)

**Appendix D**

Numerical rating scale

Pain and medication Dairy

PGIC

MQS III

Medication list

OKS

Goniometry

Timed up and go test

EQ-5D-5L

HADS

PCS

Cost diary

NL69877.068.19

Cocogen Trial

**Appendix E**

Table 1: Overview study procedures per site visit

Site visit	Study procedures at site	Study procedures at home
T0: baseline	<ul style="list-style-type: none"> <li>- MQS III</li> <li>- Goniometry</li> <li>- Timed up and go test</li> </ul>	<ul style="list-style-type: none"> <li>- NRS</li> <li>- Is pain acceptable?</li> <li>- Medication list</li> <li>- OKS</li> <li>- EQ-5D-5L</li> <li>- HADS</li> <li>- PCS</li> <li>- Cost diary</li> </ul>
T1: 1 months post intervention	<ul style="list-style-type: none"> <li>- Adverse Events</li> <li>- MQS III</li> </ul>	<ul style="list-style-type: none"> <li>- NRS</li> <li>- Is pain acceptable?</li> <li>- PGIC</li> <li>- Medication list</li> <li>- EQ5-5D-5L</li> <li>- Cost diary</li> </ul>
T2: 3 months post intervention	<ul style="list-style-type: none"> <li>- Adverse Events</li> <li>- MQS III</li> <li>- Goniometry</li> <li>- Timed up and go test</li> </ul>	<ul style="list-style-type: none"> <li>- NRS</li> <li>- Is pain acceptable?</li> <li>- PGIC</li> <li>- Medication list</li> <li>- OKS</li> <li>- EQ-5D-5L</li> <li>- Cost diary</li> <li>- HADS</li> <li>- PCS</li> </ul>
T3: 6 months post intervention	<ul style="list-style-type: none"> <li>- Adverse Events</li> <li>- MQS III</li> <li>- Goniometry</li> <li>- Timed up and go test</li> </ul>	<ul style="list-style-type: none"> <li>- NRS</li> <li>- Is pain acceptable?</li> <li>- PGIC</li> <li>- Medication list</li> <li>- Cost diary</li> <li>- OKS</li> <li>- EQ-5D-5L</li> <li>- HADS</li> <li>- PCS</li> </ul>
T4: 12 months	/	- NRS

NL69877.068.19

Cocogen Trial

post intervention		<ul style="list-style-type: none"><li>- Is pain acceptable?</li><li>- PGIC</li><li>- Medication list</li><li>- Cost diary</li><li>- OKS</li><li>- EQ-5D-5L</li><li>- HADS</li><li>- PCS</li><li>- Adverse Events</li><li>- Performance of TKA?</li></ul>
----------------------	--	--